1348 genotypes with 1849 annotations displayed
of selected term and subterms
|
Searched Term: autoimmune response
|
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(NOD.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/Jdk)
|
decreased susceptibility to autoimmune diabetes
|
J:137009
|
\AA467197em1Nyam/\AA467197em1Nyam
(C.B6-AA467197em1Nyam)
|
increased susceptibility to autoimmune disorder
|
J:347271
|
\Abattm1c(EUCOMM)Hmgu/\Abattm1c(EUCOMM)Hmgu \Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
\Acantm2Afos/\Acantm2Afos
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:122102
|
\Ackr4tm1.1Rjbn/\Ackr4tm1.1Rjbn
(B6.129S6-Ackr4tm1.1Rjbn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:166490
|
\Acla1BXSB/Slc/\Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Acla1NZW/Slc/\Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Acla2BXSB/Slc/\Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Acla2NZW/Slc/\Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Actbtm4(cre/ERT2)Npa/\Actb+ \Sgpl1tm1.1Npa/\Sgpl1tm1.1Npa
(involves: BALB/cJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199525
|
\Adam8tm1.1Mdz/\Adam8tm1.1Mdz
(DBA/1LacJ-Adam8tm1.1Mdz)
|
decreased susceptibility to induced arthritis
|
J:155243
|
\Adamts5tm1.1Eam/\Adamts5+
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
\Adamts5tm1.1Eam/\Adamts5tm1.1Eam
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
\Adamts5tm2.2Lex/\Adamts5tm2.2Lex
(B6.129S5-Adamts5tm2.2Lex)
|
decreased susceptibility to induced arthritis
|
J:175366
|
\Adaz1NZM2328/J/\Adaz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased anti-double stranded DNA antibody level
|
J:71397
|
\Adgrd1tm1b(EUCOMM)Wtsi/\Adgrd1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adgrd1tm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Ads1NZB/\Ads1NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7239,
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads1NZB/\Ads1NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads2NZB/\Ads2NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads2NZB/\Ads2NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads3NZB/\Ads3NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads3NZW/\Ads3NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7239
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads4NZB/\Ads4NZB
(involves: NZB * NZW)
|
decreased anti-double stranded DNA antibody level
|
J:11074
|
\Ads4NZB/\Ads4NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Ads4NZW/\Ads4NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
\Aec1NOD/Uf/\Aec1NOD/Uf \Aec2NOD/Uf/\Aec2NOD/Uf
(B6.NOD-Aec2NOD/Uf Aec1NOD/Uf)
|
increased anti-nuclear antigen antibody level
|
J:129282
|
increased susceptibility to autoimmune disorder
|
J:128900
|
\Aem1C57BL/6/\Aem1NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:7191
|
\Aem2C57BL/6/\Aem2C57BL/6
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
\Aem2C57BL/6/\Aem2NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
\Aem2C57BL/6/\Aem2NZB \Aem3C57BL/6/\Aem3NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
\Agnm1MRL/MpJ/\Agnm1MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
\Agnm2C3H/HeJ/\Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
\Agnm2MRL/MpJ/\Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
\Agnm3C3H/HeJ/\Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
\Agnm3MRL/MpJ/\Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
\Aia1NZB/Omr/\Aia1NZB/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
\Aia1NZB/Omr/\Aia1NZC/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
\Aif1tm1Nsib/\Aif1tm1Nsib
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:204462
|
\Aim2tm1.2Arte/\Aim2tm1.2Arte \Dnase2atm1Osa/\Dnase2atm1Osa \Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129 * BALB/c * C57BL/6 * C57BL/6J)
|
increased autoantibody level
|
J:238323
|
rheumatoid arthritis
|
J:238323
|
\Airetm1.1Doi/\Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6)
|
increased autoantibody level
|
J:119475
|
increased susceptibility to autoimmune disorder
|
J:83422
|
\Airetm1.1Doi/\Airetm1.1Doi
(B6.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
\Airetm1.1Doi/\Airetm1.1Doi
(NOD.129S2(B6)-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
\Airetm1.1Doi/\Airetm1.1Doi
(C.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
\Airetm1.1Doi/\Airetm1.1Doi
(SJL.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
\Airetm1Mand/\Aire+
(NOD.129P2-Airetm1Mand)
|
increased autoantibody level
|
J:188686
|
increased susceptibility to autoimmune diabetes
|
J:135154,
J:188686
|
\Airetm1Mmat/\Airetm1Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:96580
|
\Airetm1Mmat/\Airetm1Mmat
(C.Cg-Airetm1Mmat)
|
increased autoantibody level
|
J:96580
|
\Airetm1Mmat/\Airetm1Mmat
(B6.Cg-Airetm1Mmat)
|
autoimmune response
|
J:96580
|
\Airetm1Mmat/\Airetm2Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:141379
|
\Airetm1Pltn/\Airetm1Pltn
(involves: 129S4/SvJae * C57BL/6)
|
increased autoantibody level
|
J:77873
|
\Airetm1Ptsn/\Airetm1Ptsn
(C57BL/6-Airetm1Ptsn)
|
increased autoantibody level
|
J:145910
|
\Airetm1Ptsn/\Airetm1Ptsn
(C.B6-Airetm1Ptsn)
|
increased susceptibility to autoimmune disorder
|
J:174653
|
\Airetm2Mmat/\Airetm2Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:141379
|
\Alox5tm1Fun/\Alox5tm1Fun
(B6.129S2-Alox5tm1Fun/J)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:108446
|
\Alox5aptm1Jdm/\Alox5ap+
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased susceptibility to induced arthritis
|
J:100736
|
\Alox5aptm1Jdm/\Alox5aptm1Jdm
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased susceptibility to induced arthritis
|
J:100736
|
\anan/\anan
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
\anan/\anan+
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
\anaya/\anaya
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
\andra/\andra
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
\Anta/\Anta+
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
\Apcstm1Mpe/\Apcs+
(B6.Cg-Apcstm1Mpe)
|
increased autoantibody level
|
J:90502
|
\Apcstm1Mpe/\Apcstm1Mpe
(B6.Cg-Apcstm1Mpe)
|
increased autoantibody level
|
J:90502
|
\Apcstm1Smae/\Apcstm1Smae
(involves: 129S/SvEv * C57BL/6)
|
increased autoantibody level
|
J:71194
|
\Apoetm1Unc/\Apoetm1Unc
(B6.129P2-Apoetm1Unc/J)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
\Apoetm1Unc/\Apoetm1Unc
(B6.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
\Apoetm1Unc/\Apoetm1Unc \Faslpr/\Faslpr
(MRL.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
\Apoetm1Unc/\Apoetm1Unc \Faslpr/\Faslpr
(B6.Cg-Apoetm1Unc Faslpr)
|
decreased autoantibody level
|
J:121671
|
increased anti-double stranded DNA antibody level
|
J:121671
|
increased autoantibody level
|
J:121671
|
\Apoetm1Unc/\Apoetm1Unc \Faslgld/\Faslgld
(B6.Cg-Faslgld Apoetm1Unc)
|
increased anti-nuclear antigen antibody level
|
J:200141,
J:91058
|
increased autoantibody level
|
J:91058
|
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu \Sting1em1Jmin/\Sting1em1Jmin \Commd10Tg(Vav1-icre)A2Kio/\Commd10+
(Not Specified)
|
decreased susceptibility to autoimmune disorder
|
J:363611
|
\Arid5atm1Rnis/\Arid5atm1Rnis
(B6.Cg-Arid5atm1Rnis)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:197418
|
\Arigg1NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg8BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg9NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Arigg10BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
\Art2atm1Fkn/\Art2atm1Fkn \Art2btm1Fkn/\Art2btm1Fkn \Cd38tm1Lnd/\Cd38tm1Lnd
(NOD.129(B6)-Cd38tm1Lnd Art2atm1Fkn Art2btm1Fkn/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:108097
|
\asa/\asa
(either: A/J or BALB/c or DBA/2J)
|
increased autoantibody level
|
J:2843
|
\Asbb1BALB/c/\Asbb1BALB/c
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
\Asbb2BALB/c/\Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
\Asbb2C57BL/6J/\Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
\Asbb3C57BL/6J/\Asbb3C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu
(B6.FVB-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu)
|
increased autoantibody level
|
J:208213
|
increased susceptibility to autoimmune disorder
|
J:208213
|
increased susceptibility to induced arthritis
|
J:208213
|
\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu \Il6tm1Kopf/\Il6tm1Kopf
(B6.Cg-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf)
|
increased susceptibility to induced arthritis
|
J:208213
|
\Atg5tm1Myok/\Atg5tm1Myok \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Atg7tm1Tchi/\Atg7tm1Tchi \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Atxn3tm1a(KOMP)Wtsi/\Atxn3tm1a(KOMP)Wtsi
(C57BL/6N-Atxn3tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Aviltm2(cre)Fawa/\Aviltm2(cre)Fawa
(B6J.129P2-Aviltm2(cre)Fawa)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:265529
|
\Axltm1Grl/\Axltm1Grl \Mertktm1Grl/\Mertktm1Grl
(involves: C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
\Axltm1Grl/\Axltm1Grl \Mertktm1Grl/\Mertktm1Grl \Tyro3tm1Grl/\Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal susceptibility to autoimmune disorder
|
J:70420
|
increased anti-double stranded DNA antibody level
|
J:70420
|
increased autoantibody level
|
J:70420
|
\Axltm1Grl/\Axltm1Grl \Tyro3tm1Grl/\Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
\B2mtm1Unc/\B2mtm1Unc
(NOD.129P2-B2mtm1Unc)
|
decreased susceptibility to autoimmune diabetes
|
J:121685,
J:17000
|
\B2mtm1Unc/\B2mtm1Unc
(B6.129P2-B2mtm1Unc/DcrJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
\B2mtm1Unc/\B2mtm1Unc \Ciitatm1Ccum/\Ciitatm1Ccum
(NOD.Cg-B2mtm1Unc Ciitatm1Ccum)
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
\B2mtm1Unc/\B2mtm1Unc \Emv30b/\Emv30b \Prkdcscid/\Prkdcscid \Tg(B2M)55Hpl/? \Mcph1Tg(HLA-A2.1)1Enge/?
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Emv30b Prkdcscid Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
\B2mtm1Unc/\B2mtm1Unc \Tg(B2M)55Hpl/0
(NOD.Cg-B2mtm1Unc Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:71837
|
\B2mtm1Unc/\B2mtm1Unc \Tg(B2M)55Hpl/\Tg(B2M)55Hpl \Mcph1Tg(HLA-A2.1)1Enge/\Mcph1Tg(HLA-A2.1)1Enge
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Tg(B2M)55Hpl)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
\B2mtm1Unc/\B2mtm1Unc \Tg(GFAP-B2m)9Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
\B2mtm1Unc/\B2mtm1Unc \Tg(GFAP-B2m)#Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
\B2mtm1Unc/\B2mtm1Unc \Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
\B2mtm1Unc/\B2mtm1Unc \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
\B2mtm1Unc/\B2mtm1Unc X/\Yaa
(BXSB.129P2(B6)-B2mtm1Unc/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv \Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123547
|
increased anti-double stranded DNA antibody level
|
J:123547
|
increased anti-nuclear antigen antibody level
|
J:123547
|
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv \Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
\B9d2/Tgfb1tm1Flv/\B9d2+ \Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
\Bak1tm1Thsn/\Bak1tm1Thsn \Baxtm1Sjk/\Baxtm2Sjk \Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased anti-double stranded DNA antibody level
|
J:100463
|
increased susceptibility to autoimmune disorder
|
J:100463
|
\Batftm1.1Kmm/\Batftm1.1Kmm
(129S6/SvEvTac-Batftm1.1Kmm)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150643
|
\Bcl2l1tm1Cant/\Bcl2l1tm1Cant
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:77507
|
\Bcl2l11tm1.1Ast/\Bcl2l11+
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:58641
|
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(involves: 129S1/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to autoimmune disorder
|
J:58641
|
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast \Faslpr/\Faslpr
(B6.Cg-Bcl2l11tm1.1Ast Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to autoimmune disorder
|
J:132217
|
\Becn1tm1.1Bflu/\Becn1tm1.1Bflu \Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203090
|
\Becn1tm1Ebr/\Becn1tm1Ebr \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Bhlhe40tm1Tan/\Bhlhe40tm1Tan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal susceptibility to autoimmune disorder
|
J:72651
|
increased anti-nuclear antigen antibody level
|
J:72651
|
\Blnktm1Dkit/\Blnktm1Dkit
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:94297
|
\Bmxtm1Ali/\Bmxtm1Ali
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to induced arthritis
|
J:173099
|
\Bsgtm1Tmu/\Bsgtm1Tmu
(involves: 129S2/SvPas)
|
increased susceptibility to systemic lupus erythematosus
|
J:287636
|
\Btkxid/? \Ptpn6me/\Ptpn6me
(involves: C57BL/6J * CBA/N * NFS)
|
increased autoantibody level
|
J:30994
|
\Btkxid/\Btkxid
(CBA/CaHN-Btkxid/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92639
|
\Btkxid/\Btkxid
(CBA/HN-Btkxid)
|
autoimmune response
|
J:125114
|
\Btlatm1Kmm/\Btlatm1Kmm
(involves: 129S/SvEv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84084
|
\Btn2a2tm1.2Wrth/\Btn2a2tm1.2Wrth
(C57BL/6-Btn2a2tm1.2Wrth)
|
increased anti-nuclear antigen antibody level
|
J:232636
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:232636
|
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
increased autoantibody level
|
J:145903
|
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
(B10.BXSB-(D13Mit3-D13Mit78))
|
autoimmune response
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ \Gpab1C57BL/6J/?
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
increased autoantibody level
|
J:145903
|
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ X/\Yaa
(B10.BXSB-(D13Mit3-D13Mit78) Yaa)
|
autoimmune response
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
\C1qatm1Mjw/\C1qatm1Mjw
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-histone antibody level
|
J:47315
|
increased anti-nuclear antigen antibody level
|
J:47315
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle16129S6/SvEvTac/\Sle16129S6/SvEvTac
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle16129S6/SvEvTac/\Sle16C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle18C57BL/6/\Sle18C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle18C57BL/6/\Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle19C57BL/6/?
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle19C57BL/6/?
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle21129P2/Ola/? \Sle18C57BL/6/\Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle21129P2/Ola/\Sle21129P2/Ola
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qatm1Mjw/\C1qatm1Mjw \Sle21129P2/Ola/\Sle21C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
\C1qtnf3tm1Yiw/\C1qtnf3tm1Yiw
(involves: C57BL/6NSlc)
|
increased susceptibility to induced arthritis
|
J:211893
|
\C1qtnf6tm1Yiw/\C1qtnf6tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:227217
|
increased autoantibody level
|
J:227217
|
\C1qtnf6tm1Yiw/\C1qtnf6tm1Yiw
(B6.129P2-C1qtnf6tm1Yiw)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:227217
|
increased susceptibility to induced arthritis
|
J:227217
|
\C3tm1Crr/\C3tm1Crr
(B6.129S4-C3tm1Crr)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
\C3tm1Crr/\C3tm1Crr \C4btm1Crr/\C4btm1Crr \Faslpr/\Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
\C3tm1Crr/\C3tm1Crr \Faslpr/\Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
decreased susceptibility to autoimmune disorder
|
J:127292
|
\C3tm1Crr/\C3tm1Crr \Fcer1gtm1Rav/\Fcer1gtm1Rav \Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
\C3tm1Crr/\C3tm1Crr \Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
\C3tm1Pkna/\C3tm1Pkna
(D1.129P2-C3tm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
\C3ar1tm1Raw/\C3ar1tm1Raw
(B6.129X1(B6)-C3ar1tm1Raw)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:93791
|
\C4btm1Crr/\C4btm1Crr
(involves: 129S4/SvJae * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:111811
|
increased anti-nuclear antigen antibody level
|
J:111811
|
increased anti-single stranded DNA antibody level
|
J:111811
|
\C4btm1Crr/\C4btm1Crr \Faslpr/\Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
\C9orf72em1Eggn/\C9orf72em1Eggn
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
\C9orf72tm1.1Eggn/\C9orf72+
(involves: C57BL/6 * C57BL/6N)
|
increased autoantibody level
|
J:240357
|
\C9orf72tm1.1Eggn/\C9orf72tm1.1Eggn
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased autoantibody level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
\C9orf72tm1Eggn/\C9orf72tm1Eggn
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
\Card19tm1Rwen/\Card19tm1Rwen
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased autoantibody level
|
J:336763
|
\Casp1tm1Flv/\Casp1tm1Flv \Casp4del/\Casp4del
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57101
|
\Cblbtm1Hua/\Cblbtm1Hua
(B6.129P2-Cblbtm1Hua)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
\Cblbtm1Hua/\Cblbtm1Hua \Ubash3btm1Jni/\Ubash3btm1Jni \Ubash3atm1Jni/\Ubash3atm1Jni
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
\Ccl2tm1Rol/\Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
\Ccl2tm1Rol/\Ccl2tm1Rol
(SJL.129S4-Ccl2tm1Rol)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
\Ccl4em1Narl/\Ccl4em1Narl
(C57BL/6JNarl-Ccl4em1Narl)
|
decreased susceptibility to autoimmune diabetes
|
J:346348
|
\Ccnt1Gt(RRR115)Byg/\Ccnt1Gt(RRR115)Byg
(involves: 129P2/OlaHsd)
|
autoimmune response
|
J:130071
|
\Ccr1tm1Cge/\Ccr1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:63952
|
\Ccr2tm1Ifc/\Ccr2tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:75838
|
\Ccr2tm2.1Ifc/\Ccr2tm2.1Ifc \Cx3cr1tm1Litt/\Cx3cr1+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
\Ccr2tm2.1Ifc/\Ccr2tm2.1Ifc \Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
\Ccr6tm1Lira/\Ccr6tm1Lira
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148286
|
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(B6.129P2-Ccr7tm1Rfor)
|
increased susceptibility to autoimmune disorder
|
J:110910
|
\Ccr8tm1Lira/\Ccr8tm1Lira
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
\Cd1d1tm1Crw/\Cd1d1tm1Crw
(B6.129S4-Cd1d1tm1Crw)
|
decreased susceptibility to induced arthritis
|
J:99107
|
\Cd1d1tm1Luc/\Cd1d1tm1Luc
(B6.129S6-Cd1d1tm1Luc)
|
autoimmune response
|
J:122245
|
\Cd1d1tm1Luc/\Cd1d1tm1Luc
(C.129S6-Cd1d1tm1Luc)
|
increased anti-double stranded DNA antibody level
|
J:121187
|
increased anti-nuclear antigen antibody level
|
J:121187
|
\Cd1d1tm1Luc/\Cd1d1tm1Luc \Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(B6.129-Cd1d1tm1Luc Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
\Cd4tm1(cre/ERT2)Thbu/\Cd4+ \Gfm1tm1c(EUCOMM)Wtsi/\Gfm1tm1c(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:302272
|
\Cd4tm1Knw/\Cd4tm1Knw
(NOD.Cg-Cd4tm1Knw)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
\Cd4tm1Knw/\Cd4tm1Knw \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
\Cd4tm1Mak/\Cd4tm1Mak \Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(B6.Cg-Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
\Cd5tm1.1Chra/\Cd5tm1.1Chra
(involves: C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
\Cd5tm1Cgn/\Cd5tm1Cgn
(B6.129P2-Cd5tm1Cgn)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
\Cd8atm1Mak/\Cd8atm1Mak \Il15tm1Imx/\Il15tm1Imx X/\Yaa
(BXSB.Cg-Cd8atm1Mak Il15tm1Imx/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\Cd8atm1Mak/\Cd8atm1Mak X/\Yaa
(BXSB.129S2(B6)-Cd8atm1Mak/4Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\Cd19tm1(cre)Cgn/\Cd19+ \Ep300tm2Reck/\Ep300+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:147840
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
\Cd19tm1(cre)Cgn/\Cd19+ \Ep300tm2Reck/\Ep300+
(involves: 129/Sv * 129P2/OlaHsd * FVB/N)
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
\Cd19tm1(cre)Cgn/\Cd19+ \Fastm1Ach/\Fastm1Ach
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
\Cd19tm1(cre)Cgn/\Cd19+ \Fastm1Cgn/\Fastm1Cgn
(B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
\Cd19tm1(cre)Cgn/\Cd19+ \Gt(ROSA)26Sortm2(Cd74/MOG)Awai/\Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
\Cd19tm1(cre)Cgn/\Cd19+ \Gt(ROSA)26Sortm2(Cd74/MOG)Awai/\Gt(ROSA)26Sor+ \Il10tm1Roer/\Il10tm1Roer
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
\Cd19tm1(cre)Cgn/\Cd19+ \Ptpn6tm1Rsky/\Ptpn6tm1Rsky
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:123568
|
\Cd19tm1(cre)Cgn/\Cd19+ \Tnfaip3tm1.1Awai/\Tnfaip3tm1.1Awai
(involves: 129P2/OlaHsd)
|
increased anti-nuclear antigen antibody level
|
J:175422
|
\Cd19tm1(cre)Cgn/\Cd19+ \Tnfaip3tm2Ama/\Tnfaip3+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased autoantibody level
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
\Cd19tm1Tft/\Cd19tm1Tft
(B6.Cg-Cd19tm1Tft)
|
decreased anti-double stranded DNA antibody level
|
J:136210
|
decreased anti-nuclear antigen antibody level
|
J:136210
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:106487
|
\Cd19tm1Tft/\Cd19tm1Tft \Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased anti-double stranded DNA antibody level
|
J:71174
|
decreased susceptibility to systemic lupus erythematosus
|
J:71174
|
\Cd22tm1Msn/\Cd22tm1Msn
(either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))
|
increased anti-double stranded DNA antibody level
|
J:76974,
J:76975
|
\Cd22tm2Lnit/\Cd22tm2Lnit
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:198790
|
\Cd22tm3Lnit/\Cd22tm3Lnit
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
autoimmune response
|
J:198790
|
\Cd28tm1Jmg/\Cd28tm1Jmg
(B6.129X1-Cd28tm1Jmg)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
\Cd28tm1Ltu/\Cd28tm1Ltu \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:194503
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:194503
|
\Cd28tm1Mak/\Cd28tm1Mak
(NOD.129S2-Cd28tm1Mak)
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
\Cd28tm1Mak/\Cd28tm1Mak
(B6.129S2-Cd28tm1Mak/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
\Cd28tm1Mak/\Cd28tm1Mak \Cd40lgtm1Flv/\Cd40lgtm1Flv
(NOD.Cg-Cd40lgtm1Flv Cd28tm1Mak)
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
\Cd28tm1Shr/\Cd28tm1Shr \Ctla4tm1Shr/\Ctla4+
(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
|
increased susceptibility to autoimmune disorder
|
J:125259
|
\Cd38tm1Lnd/\Cd38tm1Lnd
(NOD.129P2(B6)-Cd38tm1Lnd/LtJ)
|
increased susceptibility to autoimmune diabetes
|
J:108097
|
\Cd40tm1Kik/\Cd40tm1Kik \Tg(Tnfsf13b)1Fma/?
(B6.Cg-Cd40tm1Kik Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
\Cd40lgtm1Flv/Y \Faslpr/\Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
\Cd40lgtm1Flv/Y \Faslpr/\Faslpr \Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
\Cd40lgtm1Flv/\Cd40lgtm1Flv
(NOD.129S2-Cd40lgtm1Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:93421
|
\Cd40lgtm1Flv/\Cd40lgtm1Flv \Faslpr/\Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
\Cd40lgtm1Flv/\Cd40lgtm1Flv \Faslpr/\Faslpr \Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
(B6.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
(SJL.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
\Cd44tm1Mak/\Cd44tm1Mak
(D1.129P2-Cd44tm1Mak)
|
increased susceptibility to induced arthritis
|
J:95275
|
\Cd44tm2.1Ugu/\Cd44tm2.1Ugu
(B6.129-Cd44tm2.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
\Cd44tm2Kmz/\Cd44tm2Kmz
(DBA/1LacJ-Cd44tm2Kmz)
|
decreased susceptibility to induced arthritis
|
J:74268
|
\Cd55tm1Mme/\Cd55tm1Mme
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:80116
|
\Cd55tm1Song/\Cd55tm1Song
(B6.129S6-Cd55tm1Song)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
\Cd55tm1Song/\Cd55tm1Song \Cd59atm1Bpm/\Cd59atm1Bpm
(B6.129-Cd55tm1Song Cd59atm1Bpm)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
\Cd59atm1Bpm/\Cd59atm1Bpm
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89014
|
\Cd59atm1Bpm/\Cd59atm1Bpm
(involves: 129)
|
increased susceptibility to induced arthritis
|
J:146711
|
\Cd59atm1Bpm/\Cd59atm1Bpm
(B6.129-Cd59atm1Bpm)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
\Cd69tm1Naka/\Cd69tm1Naka
(C.129P2-Cd69tm1Naka)
|
decreased susceptibility to induced arthritis
|
J:84940
|
\Cd72b/\Cd72b \Faslpr/\Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
decreased anti-double stranded DNA antibody level
|
J:204782
|
decreased anti-nuclear antigen antibody level
|
J:204782
|
decreased susceptibility to autoimmune disorder
|
J:204782
|
\Cd72c/\Cd72c \Faslpr/\Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
increased susceptibility to systemic lupus erythematosus
|
J:204782
|
\Cd72tm1Tsub/\Cd72tm1Tsub
(involves: C57BL/6J)
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
\Cd72tm1Tsub/\Cd72tm1Tsub \Faslpr/\Faslpr
(involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
\Cd74tm1Liz/\Cd74tm1Liz
(B6.129S-Cd74tm1Liz)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
\Cd74tm2Liz/\Cd74tm2Liz
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
\Cd74tm3Liz/\Cd74tm3Liz
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
\Cd79atm1(cre)Reth/\Cd79a+ \Inpp5dtm1Rav/\Inpp5dtm1Rav
(involves: 129 * BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:178833
|
increased anti-double stranded DNA antibody level
|
J:178833
|
increased anti-nuclear antigen antibody level
|
J:178833
|
increased anti-single stranded DNA antibody level
|
J:178833
|
increased autoantibody level
|
J:178833
|
increased susceptibility to systemic lupus erythematosus
|
J:178833
|
\Cd79atm1(cre)Reth/\Cd79a+ \Wastm1.1Ldn/Y
(involves: BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
\Cd79atm1(cre)Reth/\Cd79a+ \Wastm1.1Ldn/\Wastm1.1Ldn
(involves: BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
\Cd79atm1.1Rsky/\Cd79atm1.1Rsky
(involves: C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:179254
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm1Shr/\Cd86tm1Shr
(B6.129S4-Cd80tm1Shr Cd86tm1Shr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm2Shr/\Cd86tm2Shr
(involves: 129S4/SvJae)
|
increased susceptibility to autoimmune diabetes
|
J:113109
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm2Shr/\Cd86tm2Shr
(involves: 129S4/SvJae * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:61905
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm2Shr/\Cd86tm2Shr
(129.SJL-Cd86tm2Shr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm2Shr/\Cd86tm2Shr
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
\Cd80tm1Shr/\Cd80tm1Shr \Cd86tm2Shr/\Cd86tm2Shr \Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(involves: 129S4/SvJae * FVB/N * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
\Cd86tm1Shr/\Cd86tm1Shr
(NOD.129S4-Cd86tm1Shr)
|
decreased susceptibility to autoimmune diabetes
|
J:71352
|
increased autoantibody level
|
J:142046
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
\Cd180tm1Kmiy/\Cd180tm1Kmiy \Faslpr/\Faslpr
(MRL.Cg-Cd180tm1Kmiy Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
\Cd200tm1Jods/\Cd200tm1Jods
(C57BL/6-Cd200tm1Jods)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:65982
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:79906
|
increased susceptibility to induced arthritis
|
J:65982
|
\Cd247tm2.1Lov/\Cd247tm2.1Lov
(B6.Cg-Cd247tm2.1Lov)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:192915
|
\Cd274tm1.1Lex/\Cd274tm1.1Lex
(involves: 129S5/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
\Cd274tm1Lpc/\Cd274tm1Lpc
(B6.129S-Cd274tm1Lpc)
|
increased susceptibility to autoimmune disorder
|
J:89781
|
\Cd274tm1Lpc/\Cd274tm1Lpc
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142815
|
\Cd274tm1Lpc/\Cd274tm1Lpc
(C.129S-Cd274tm1Lpc)
|
increased susceptibility to induced arthritis
|
J:165841
|
\Cd274tm1Shr/\Cd274tm1Shr
(C.B6-Cd274tm1Shr)
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
\Cd274tm1Shr/\Cd274tm1Shr \Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
\Cd276tm1Lpc/\Cd276tm1Lpc
(B6.129-Cd276tm1Lpc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:237700
|
\Cd276tm1Lpc/\Cd276tm1Lpc
(D1J.129-Cd276tm1Lpc)
|
decreased susceptibility to induced arthritis
|
J:237700
|
\Cd276tm1Mak/\Cd276tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:84973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84973
|
\Cd300lftm1Gne/\Cd300lftm1Gne
(involves: C57BL/6N)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:156819
|
\Cdk2tm2Sgo/\Cdk2tm2Sgo \Cdk4tm2.1Bbd/\Cdk4tm2.1Bbd \Polr2atm1(cre/ERT2)Bbd/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:125217
|
\Cdk4tm1Kiyo/\Cdk4+ \Lin9tm1Orc/\Lin9+
(involves: 129S1/Sv)
|
decreased susceptibility to autoimmune diabetes
|
J:111333
|
\Cdkn1atm1Led/\Cdkn1atm1Led
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
\Cdkn1atm1Led/\Cdkn1atm1Led \Gadd45atm1Ajf/\Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
(B6;129S2-Cdkn1atm1Tyj/J)
|
decreased susceptibility to induced arthritis
|
J:108569
|
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:60292
|
increased anti-histone antibody level
|
J:60292
|
increased anti-nuclear antigen antibody level
|
J:60292
|
\Ceat1CBA/J/\Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
\Ceat1NOD/\Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
\Cfbtm1Pkna/\Cfbtm1Pkna
(D1.129P2-Cfbtm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
\Cfptm1Song/\Cfptm1Song
(involves: 129 * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:165497
|
\Cfptm2.1Song/\Cfptm2.1Song \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased susceptibility to induced arthritis
|
J:165497
|
\Cgnz1NZM2328/J/\Cgnz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased susceptibility to systemic lupus erythematosus
|
J:71397
|
\Chuktm2Mka/\Chuktm2Mka \Tg(Tnfsf13b)1Fma/?
(B6.Cg-Chuktm2Mka Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
\Cia2DBA/1J/\Cia2DBA/1J
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:116665
|
\Cia5bRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
\Cia5bRIIIS/J/\Cia5bRIIIS/J \Cia32B10.RIII/\Cia32RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
\Cia5cRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
\Cia7DBA/1J/\Cia7DBA/1J
(involves: B10.Q * DBA/1)
|
increased susceptibility to induced arthritis
|
J:122130
|
\Cia30RIIIS/J/\Cia30RIIIS/J \Cia5B10.RIII/\Cia5B10.RIII
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
\Cia31B10.RIII/\Cia31RIIIS/J \Cia5RIIIS/J/\Cia5RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
\Cia34DBA/1J/\Cia34DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
\Cia35C57BL/10SnSg/\Cia35C57BL/10SnSg \Cia42DBA/1J/\Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
\Cia35C57BL/10SnSg/\Cia35DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
\Cia35C57BL/10SnSg/\Cia35DBA/1J \Cia42DBA/1J/\Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
\Cia35DBA/1J/\Cia35DBA/1J \Cia42DBA/1J/\Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
\Cia36DBA/1J/\Cia36DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
\Cia37C57BL/10SnSg/\Cia37DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
\Cia38DBA/1J/\Cia38DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
\Cia39C57BL/10Sn/\Cia39C57BL/10Sn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
|
decreased susceptibility to induced arthritis
|
J:97801
|
\Cia40C57BL/10SnSg/\Cia40C57BL/10SnSg
(involves: C57BL/10SnSg * DBA/1J * NFS/N)
|
increased susceptibility to induced arthritis
|
J:106522
|
\Cia43DBA/1J/\Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
\Cia43FVB/N/\Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
\Ciaaq1DBA/1J/\Ciaaq1DBA/1J
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
\Ciaaq1DBA/1J/\Ciaaq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
\Ciitatm1Ccum/\Ciitatm1Ccum
(NOD.129S2(B6)-Ciitatm1Ccum)
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
\Ciitatm1Jpyt/\Ciitatm1Jpyt
(B6.129P2-Ciitatm1Jpyt)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
\Clec1atm1Yiw/\Clec1atm1Yiw
(involves: C57BL/6J * C57BL/6NSlc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:329240
|
\Clec4a2tm1Yiw/\Clec4a2tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:217720
|
increased autoantibody level
|
J:217720
|
increased susceptibility to induced arthritis
|
J:217720
|
\Clec4dtm1.1Shoy/\Clec4dtm1.1Shoy
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
\Clec4etm1Tks/\Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
\Clec5atm1Cua/\Clec5atm1Cua
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:158811
|
\Cntftm1Mpin/\Cntftm1Mpin
(B6.129S2-Cntftm1Mpin)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126852
|
\Cog6tm1a(EUCOMM)Wtsi/\Cog6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cog6tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Col17a1tm1Shzu/\Col17a1tm1Shzu \Tg(KRT14-COL17A1)1Shzu/0
(involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)
|
decreased autoantibody level
|
J:121695
|
\Col17a1tm1Tiin/\Col17a1tm1Tiin
(involves: C57BL/6)
|
increased autoantibody level
|
J:220622
|
\Coro1aLmb3-C57BL/6Scr/\Coro1aLmb3-C57BL/6Scr
(MRL.Cg-Coro1aC57BL/6Scr Faslpr)
|
decreased autoantibody level
|
J:125557
|
decreased susceptibility to systemic lupus erythematosus
|
J:125557
|
\Coro1aLmb3-MRL/MpScr/\Coro1aLmb3-MRL/MpScr
(B6.MRL-Coro1aMRL/MpScr Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:125557
|
\Cr2tm1Crr/\Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:111811
|
\Crhtm1Maj/\Crhtm1Maj
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98419
|
\Cry1tm1Jhjh/\Cry1tm1Jhjh \Cry2tm1Jhjh/\Cry2tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:159504
|
\Csf2tm1Dran/\Csf2tm1Dran \Il3tm1Glli/\Il3tm1Glli
(B6.129S2-Csf2tm1Dran Il3tm1Glli)
|
increased anti-double stranded DNA antibody level
|
J:83086
|
\Csf2tm1Mlg/\Csf2tm1Mlg
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148120
|
\Csf3tm1Ard/\Csf3tm1Ard \Junbtm3Wag/\Junbtm3Wag \Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
\Ctla4tm1Saka/\Ctla4tm1Saka \Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
increased autoantibody level
|
J:140085
|
\Ctla4tm1Shr/\Ctla4tm1Shr
(B6.129S4-Ctla4tm1Shr)
|
autoimmune response
|
J:146644
|
\Ctsbtm1Jde/\Ctsb+
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
\Ctsbtm1Jde/\Ctsbtm1Jde
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
\Ctsltm1Cptr/\Ctsl+
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
\Ctsltm1Cptr/\Ctsltm1Cptr
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
\Ctsstm1Eae/\Ctsstm1Eae
(involves: C57BL/6 * DBA/1LacJ)
|
decreased susceptibility to induced arthritis
|
J:53399
|
\Ctsstm1Eae/\Ctsstm1Eae
(NOD.D1-Ctsstm1Eae)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
\Ctsstm1Hap/\Ctsstm1Hap
(B6.129S2-Ctsstm1Hap)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:96401
|
\Cx3cr1tm1Litt/\Cx3cr1+
(B6.129P2-Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(B6.129P2-Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
\Cxcl10tm1Adl/\Cxcl10tm1Adl
(B6.129S4-Cxcl10tm1Adl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87076
|
\Cxcr2tm1a(EUCOMM)Wtsi/\Cxcr2tm1a(EUCOMM)Wtsi
(C57BL/6N-Cxcr2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Cxcr2tm1Mwm/\Cxcr2tm1Mwm
(C.129S2(B6)-Cxcr2tm1Mwm/J)
|
decreased susceptibility to induced arthritis
|
J:142880
|
\Cxcr4tm1Yiw/\Cxcr4tm1Yiw \Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:164872
|
\Cybbtm1Din/\Cybbtm1Din
(B6.129S-Cybbtm1Din/J)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Cyp19a1tm1Esi/\Cyp19a1tm1Esi
(involves: 129S6/SvEvTac * C57BL/6)
|
increased autoantibody level
|
J:92438
|
\Cyp19a1tm1Sih/\Cyp19a1tm1Sih
(involves: 129S/SvEv)
|
increased anti-single stranded DNA antibody level
|
J:216958
|
increased autoantibody level
|
J:216958
|
increased susceptibility to autoimmune disorder
|
J:216958
|
\Cysltr2tm1Ykn/\Cysltr2tm1Ykn
(C.B6-Cysltr2tm1Ykn)
|
autoimmune response
|
J:182213
|
\Cytl1tm1Chun/\Cytl1tm1Chun
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:175377
|
\DbaclC57BL/6Jcl/\DbaclC57BL/6Jcl
(NOD.B6-(D4Mit193-D4Mit17))
|
increased susceptibility to autoimmune diabetes
|
J:144964
|
\Dcbld2tm1a(KOMP)Wtsi/\Dcbld2tm1a(KOMP)Wtsi
(C57BL/6N-Dcbld2tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Dclk1tm1a(EUCOMM)Wtsi/\Dclk1+
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Dclk1tm1a(EUCOMM)Wtsi/\Dclk1tm1a(EUCOMM)Wtsi
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Def6Gt(OST307148)Lex/\Def6Gt(OST307148)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:106469
|
\Del(1Aim2-Ifi205)1Stsn/\+ \Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn \Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw \Tg(TcraAV19AJ33)1Shima/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
\Del(14Ltb4r2-Ltb4r1)1Bodd/\+
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
\Del(14Ltb4r2-Ltb4r1)1Bodd/\Del(14Ltb4r2-Ltb4r1)1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
\Dffbem1(IMPC)Wtsi/\Dffbem1(IMPC)Wtsi
(C57BL/6N-Dffbem1(IMPC)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Dgkztm1Gak/\Dgkztm1Gak
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:293120
|
\Dh/\Dh+ \H2d/\H2d
(NZB.Cg-Dh)
|
increased anti-erythrocyte antigen antibody level
|
J:12036
|
increased anti-nuclear antigen antibody level
|
J:12036
|
increased anti-single stranded DNA antibody level
|
J:12036
|
increased autoantibody level
|
J:12036
|
\Dicer1tm1Tara/\Dicer1tm1Tara \Foxn1tm3(cre)Nrm/\Foxn1+
(involves: 129P2/OlaHsd * C57BL/6NHsd)
|
increased susceptibility to induced arthritis
|
J:180783
|
\Dnase1tm1Tmo/\Dnase1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:62549
|
\Dnase1tm1Tmo/\Dnase1tm1Tmo
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:62549
|
increased susceptibility to systemic lupus erythematosus
|
J:62549
|
\Dnase1tm1Tmo/\Dnase1tm1Tmo
(involves: 129P2/OlaHsd * CD-1)
|
decreased susceptibility to systemic lupus erythematosus
|
J:110060
|
\Dnase1tm2092.1Arte/\Dnase1tm2092.1Arte
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:277126
|
increased anti-histone antibody level
|
J:277126
|
increased anti-nuclear antigen antibody level
|
J:277126
|
increased autoantibody level
|
J:277126
|
increased susceptibility to systemic lupus erythematosus
|
J:277126
|
\Dnase2atm1Osa/\Dnase2atm1Osa \Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:114982
|
increased autoantibody level
|
J:238323
|
rheumatoid arthritis
|
J:238323,
J:114982
|
\Dnase2atm1Osa/\Dnase2atm2Osa \Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)
|
rheumatoid arthritis
|
J:114982
|
\Dntttm1Gfn/\Dntttm1Gfn \Faslpr/\Faslpr
(involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)
|
decreased autoantibody level
|
J:110248
|
\Dock2m1Hsd/\Dock2m1Hsd \Siaetm1.2Avrk/\Siaetm1.2Avrk
(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd)
|
increased anti-double stranded DNA antibody level
|
J:144035
|
increased anti-histone antibody level
|
J:144035
|
increased anti-single stranded DNA antibody level
|
J:144035
|
\Dock8pri/\Dock8pri
(involves: C57BL/6JAnu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
\Dock10tm1Thar/\Dock10tm1Thar
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:300632
|
\Dtx1tm1.1Mzl/\Dtx1tm1.1Mzl \Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
increased autoantibody level
|
J:151605
|
\Dtx1tm1.2Mzl/\Dtx1tm1.2Mzl
(B6.129-Dtx1tm1.2Mzl)
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
\Dusp1tm1Lex/\Dusp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:126383
|
\Dusp2tm1Cmac/\Dusp2tm1Cmac
(B6.Cg-Dusp2tm1Cmac)
|
decreased susceptibility to induced arthritis
|
J:112609
|
\Dusp10tm1Flv/\Dusp10tm1Flv
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92104
|
\Dusp14Gt(OST210117)Lex/\Dusp14Gt(OST210117)Lex
(B6.129S5-Dusp14Gt(OST210117)Lex)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209403
|
\Dusp22tm1Tht/\Dusp22tm1Tht
(B6.129S7-Dusp22tm1Tht)
|
increased susceptibility to autoimmune disorder
|
J:213253
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:213253
|
\E2f1tm1Meg/\E2f1tm1Meg
(NOD.Cg-E2f1tm1Meg)
|
increased susceptibility to autoimmune diabetes
|
J:93708
|
\E2f2tm1Zubi/\E2f2tm1Zubi
(involves: 129S1/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:76318
|
increased susceptibility to autoimmune disorder
|
J:76318
|
\E2f2tm1Zubi/\E2f2tm1Zubi \Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)
|
increased susceptibility to autoimmune disorder
|
J:76318
|
\Eae1A/J/\Eae1A/J
(involves: A/J * C57BL/10SnJ)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
\Eae1PL/J/\Eae1PL/J
(involves: C57BL/10SnJ * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
\Eae2RIIIS/J/\Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
\Eae4ABH/?
(involves: ABH * NOD)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
\Eae5B10.S/DvTe/\Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae5SJL/J/\Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae7B10.S/DvTe/\Eae7B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae7B10.S/DvTe/\Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae7SJL/J/\Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae9B10.S/DvTe/\Eae9SJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae10SJL/J/\Eae10SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae11SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
\Eae12SJL/J/\Eae12SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
\Eae13SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
\Eae14C57BL/10/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
\Eae17SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
\Eae18NOD/\Eae18NOD
(involves: ABH * NOD)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
\Eae26B10.RIII/\Eae26B10.RIII
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
\Eae26B10.RIII/\Eae26RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
\Eae33C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
\Eae34C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
\Eae35C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
\Eae36SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
\Eae37C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
\Eae38C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
\Eae42C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
\Eae42SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
\Eae43B10.S/DvTe/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
\Eae43B10.S/DvTe/\Eae43B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Eae44aB10.S/DvTe/\Eae44aB10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
\Eae44bB10.S/DvTe/\Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
\Eae44bSJL/J/\Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
\Ecm1tm1Bsun/\Ecm1tm1Bsun
(involves: 129 * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:168252
|
\Edil3Tg(lacZ)1Tq/\Edil3Tg(lacZ)1Tq
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:254384
|
\Elavl1tm1.1Atas/\Elavl1tm1.1Atas \Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:207013
|
\Endoutm1Tft/\Endoutm1Tft \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)
|
increased autoantibody level
|
J:208364
|
\Entpd7tm1Ktak/\Entpd7tm1Ktak
(B6.Cg-Entpd7tm1Ktak)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:191188
|
\Ephb6tm1Jwu/\Ephb6tm1Jwu
(involves: 129)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94701
|
\Erars1DBA/2J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
|
increased anti-nuclear antigen antibody level
|
J:96064
|
\Ergtm1.1Iwamo/\Ergtm1.1Iwamo \Tg(Gdf5-cre,-ALPP)1Kng/?
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased susceptibility to induced arthritis
|
J:243715
|
\Esr1tm1Ksk/\Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:88156
|
\Extl1em1Caox/\Extl1em1Caox \Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * CBA)
|
increased susceptibility to autoimmune disorder
|
J:333437
|
\F2tm2Jld/\F2+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
|
decreased susceptibility to induced arthritis
|
J:174629
|
\F2rl1tm1Wrf/\F2rl1tm1Wrf
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:81119
|
\Faddtm1Mpa/\Faddtm1Mpa \Mogtm1(cre)Gkl/\Mog+
(involves: C57BL/6 * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:167475
|
\Fam210bem1Cya/\Fam210bem1Cya
(involves: C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:351618
|
increased anti-nuclear antigen antibody level
|
J:351618
|
\Faslpr-cg/\Faslpr-cg
(CBA/KlJms-Faslpr-cg/J)
|
autoimmune response
|
J:24805,
J:81770
|
increased anti-nuclear antigen antibody level
|
J:24805
|
increased autoantibody level
|
J:81770
|
\Faslpr/\Faslpr
(MRL/Mp-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:27634,
J:131138,
J:6257
|
increased anti-erythrocyte antigen antibody level
|
J:27634
|
increased anti-nuclear antigen antibody level
|
J:27634,
J:28885
|
increased anti-single stranded DNA antibody level
|
J:27634
|
increased autoantibody level
|
J:28885
|
increased susceptibility to autoimmune disorder
|
J:108760
|
\Faslpr/\Faslpr
(NOD.MRL(B6)-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
\Faslpr/\Faslpr
(MRL/MpJ-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:92084,
J:122315,
J:7454
|
increased anti-nuclear antigen antibody level
|
J:111811,
J:92084,
J:14151,
J:7454
|
increased autoantibody level
|
J:92084,
J:14151
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
\Faslpr/\Faslpr
(NOD.MRL-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:78679
|
\Faslpr/\Faslpr
(involves: C3H * MRL/Mp)
|
autoimmune response
|
J:1060
|
increased anti-nuclear antigen antibody level
|
J:34296
|
increased susceptibility to systemic lupus erythematosus
|
J:34296
|
\Faslpr/\Faslpr
(B6.MRL-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
\Faslpr/\Faslpr
(MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:126261
|
increased anti-nuclear antigen antibody level
|
J:126261
|
\Faslpr/\Faslpr
(MRL.Cg-Irf1tm1Mak Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:114771
|
\Faslpr/\Faslpr
(C3.MRL-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
\Faslpr/\Faslpr
(B6.MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:6638,
J:135036
|
increased autoantibody level
|
J:135036,
J:7454
|
\Faslpr/\Faslpr
(AK.MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
\Faslpr/\Faslpr
(MRL/MpJ-Faslpr)
|
autoimmune response
|
J:125114
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
\Faslpr/\Faslpr
(involves: C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
\Faslpr/\Faslpr \Fcer1gtm1Tks/\Fcer1gtm1Tks
(MRL.Cg-Fcer1gtm1Tks Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:106188
|
\Faslpr/\Faslpr \Havcr1tm1Kuch/\Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:186484
|
increased autoantibody level
|
J:186484
|
increased susceptibility to systemic lupus erythematosus
|
J:186484
|
\Faslpr/\Faslpr \Hspa13tm1.1Smoc/\Hspa13tm1.1Smoc \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)
|
decreased autoantibody level
|
J:303927
|
decreased susceptibility to systemic lupus erythematosus
|
J:303927
|
\Faslpr/\Faslpr \Ifnar1tm1Agt/\Ifnar1tm1Agt
(MRL.Cg-Ifnar1tm1Agt Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:92084
|
increased autoantibody level
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
\Faslpr/\Faslpr \Ifnar1tm1Agt/\Ifnar1tm1Agt \Ifngr1tm1Agt/\Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Ifnar1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
\Faslpr/\Faslpr \Ifngtm1Ts/\Ifng+
(MRL.Cg-Ifngtm1Ts Faslpr)
|
increased autoantibody level
|
J:123834
|
\Faslpr/\Faslpr \Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
\Faslpr/\Faslpr \Ifngr1tm1Agt/\Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
\Faslpr/\Faslpr \Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(MRL.Cg-Faslpr Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
\Faslpr/\Faslpr \Ighmtm1Cgn/\Ighmtm1Cgn
(involves: 129S2/SvPas * C57BL/6 * MRL/Mp)
|
increased autoantibody level
|
J:119584
|
\Faslpr/\Faslpr \Il4tm1Cgn/\Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
\Faslpr/\Faslpr \Il27ratm1Mak/\Il27ratm1Mak
(MRL.Cg-Il27ratm1Mak Faslpr)
|
decreased anti-double stranded DNA antibody level
|
J:122148
|
decreased susceptibility to systemic lupus erythematosus
|
J:122148
|
\Faslpr/\Faslpr \Irf1tm1Mak/\Irf1+
(MRL.Cg-Irf1tm1Mak Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:114771
|
\Faslpr/\Faslpr \Irf1tm1Mak/\Irf1tm1Mak
(MRL.Cg-Irf1tm1Mak Faslpr)
|
decreased anti-double stranded DNA antibody level
|
J:114771
|
\Faslpr/\Faslpr \Itfg2Gt(OST215121)Lex/\Itfg2Gt(OST215121)Lex
(involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:205951
|
increased anti-nuclear antigen antibody level
|
J:205951
|
increased susceptibility to systemic lupus erythematosus
|
J:205951
|
\Faslpr/\Faslpr \Pou2af1tm1Pmt/\Pou2af1tm1Pmt
(involves: 129P2/OlaHsd * C57BL/6 * MRL)
|
autoimmune response
|
J:125114
|
\Faslpr/\Faslpr \Sh2d1arpl/\Sh2d1arpl
(MRL/Mp-Faslpr Sh2d1arpl)
|
increased anti-nuclear antigen antibody level
|
J:126261
|
\Faslpr/\Faslpr \Spp1tm1Rit/\Spp1tm1Rit
(involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
\Faslpr/\Faslpr \Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
\Faslpr/\Faslpr \Tg(CD2-Foxj1)#Stlp/0
(MRL.Cg-Faslpr Tg(CD2-Foxj1)#Stlp)
|
decreased susceptibility to systemic lupus erythematosus
|
J:122222
|
increased anti-nuclear antigen antibody level
|
J:122222
|
\Faslpr/\Faslpr \Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Faslpr Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
\Faslpr/\Faslpr \Tg(INS-Il10)#Sar/0
(NOD.Cg-Faslpr Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
\Faslpr/\Faslpr \Tlr7tm1Flv/Y
(involves: 129S1/Sv * C57BL/6 * MRL/Mp)
|
decreased autoantibody level
|
J:113557
|
decreased susceptibility to systemic lupus erythematosus
|
J:113557
|
increased anti-chromatin antibody level
|
J:113557
|
increased autoantibody level
|
J:113557
|
\Faslpr/\Faslpr \Tlr9tm1Aki/\Tlr9tm1Aki
(B6.Cg-Tlr9tm1Aki Faslpr)
|
autoimmune response
|
J:135036
|
\Faslpr/\Faslpr \Tlr9tm1Aki/\Tlr9tm1Aki
(MRL.Cg-Tlr9tm1Aki Faslpr)
|
decreased autoantibody level
|
J:113557
|
increased autoantibody level
|
J:113557
|
increased susceptibility to systemic lupus erythematosus
|
J:113557
|
\Faslpr/\Faslpr \Tnfrsf9tm1Byk/\Tnfrsf9tm1Byk
(MRL.Cg-Tnfrsf9tm1Byk Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:127197
|
increased susceptibility to systemic lupus erythematosus
|
J:127197
|
\Fastheo/\Fastheo
(either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))
|
increased anti-nuclear antigen antibody level
|
J:104190
|
\Fastm1Ach/\Fastm1Ach \Tg(GZMB-cre)1Jcb/?
(involves: C57BL/6 * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
\Fastm1Ach/\Fastm1Ach \Tg(Itgax-cre,-EGFP)4097Ach/?
(Not Specified)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
\Fastm1Ach/\Fastm1Ach \Tg(Lck-cre)548Jxm/?
(involves: C57BL/6 * CBA)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
\Fastm1Cgn/\Fastm1Cgn \Cd19tm1(cre)Cgn/\Cd19+ \Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
\Fastm1Cgn/\Fastm1Cgn \Mogtm1(cre)Gkl/\Mog+
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
\Fastm1Cgn/\Fastm1Cgn \Mogtm1(cre)Gkl/\Mog+ \Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
\Fastm1Cgn/\Fastm1Cgn \Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
\Fastm1Cgn/\Fastm1Cgn \Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
\Fastm1Osa/\Fastm1Osa
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:32125
|
increased anti-single stranded DNA antibody level
|
J:32125
|
increased autoantibody level
|
J:32125
|
\Fastm1Vbo/\Fastm1Vbo \Tg(Ins2-cre)25Mgn/0 \Tg(Ins2-HA)165Bri/0 \Tg(Tcra/Tcrb)1Vbo/0
(Not Specified)
|
increased susceptibility to autoimmune diabetes
|
J:85985
|
\Faslgld/\Faslgld
(C3H/HeJ-Faslgld/J)
|
increased anti-double stranded DNA antibody level
|
J:7306
|
increased anti-nuclear antigen antibody level
|
J:7306,
J:29572
|
increased autoantibody level
|
J:7306
|
\Faslgld/\Faslgld
(involves: C3H/HeJ * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
\Faslgld/\Faslgld
(B6.C3-Faslgld)
|
increased anti-nuclear antigen antibody level
|
J:91058
|
increased autoantibody level
|
J:91058
|
\Fasltm1.1Ast/\Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:153501
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
\Fasltm1.1Lest/\Fasltm1.1Lest
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:87990
|
\Fbn1tm2.1Hcd/\Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
\Fbn1tm3.1Hcd/\Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
\Fbn1Tsk/\Fbn1+
(B6.Cg-Fbn1Tsk)
|
increased autoantibody level
|
J:21987,
J:14166
|
\Fbn1Tsk/\Fbn1+ \Il4ratm1Sz/\Il4ra+
(involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)
|
increased autoantibody level
|
J:68448
|
\Fcer1gtm1Rav/\Fcer1gtm1Rav
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
\Fcer1gtm1Rav/\Fcer1gtm1Rav \Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
\Fcer1gtm1Tks/\Fcer1gtm1Tks
(C57BL/6-Fcer1gtm1Tks)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
\Fcgr1tm1Jsv/\Fcgr1tm1Jsv
(involves: 129P2/OlaHsd * BALB/c)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
decreased susceptibility to induced arthritis
|
J:83995
|
\Fcgr2btm1.2Jsv/\Fcgr2b+ X/\Yaa
(involves: C57BL/6 * FVB/N * SB/Le)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
\Fcgr2btm1.2Jsv/\Fcgr2btm1.2Jsv \Sle16C57BL/6/\Sle16C57BL/6
(involves: C57BL/6 * FVB/N)
|
increased susceptibility to induced arthritis
|
J:179175
|
\Fcgr2btm1Kgcs/\Fcgr2b+
(involves: C57BL/6)
|
increased anti-chromatin antibody level
|
J:190890
|
increased anti-double stranded DNA antibody level
|
J:190890
|
increased susceptibility to induced arthritis
|
J:190890
|
\Fcgr2btm1Ttk/\Fcgr2btm1.2Jsv \Sle21129P2/Ola/\Sle21C57BL/6
(involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:106191
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Il17atm1Yiw/\Il17atm1Yiw
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Pdcd1tm1Hon/\Pdcd1tm1Hon
(involves: 129S2/SvPas * 129S4/SvJae * BALB/c)
|
increased autoantibody level
|
J:207275
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Sle21129P2/Ola/\Sle21129P2/Ola
(B6.129S4-Fcgr2btm1Ttk)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased autoantibody level
|
J:179175
|
increased susceptibility to induced arthritis
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Tlr7tm1Flv/Y X/\Yaa
(B6.Cg-Fcgr2btm1Ttk Tlr7tm1Flv Yaa)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Traf3ip2tm1Sbn/\Traf3ip2+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
increased susceptibility to systemic lupus erythematosus
|
J:191090
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk \Traf3ip2tm1Sbn/\Traf3ip2tm1Sbn
(involves: 129 * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk X/\Yaa
(B6.Cg-Fcgr2btm1Ttk Yaa)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv
(B6.129P2-Fcgr3tm1Jsv/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
decreased susceptibility to induced arthritis
|
J:106191
|
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv \Sle21129P2/Ola/\Sle21129P2/Ola
(B6.129P2-Fcgr3tm1Jsv)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
\Fcgr4tm1.1Rav/\Fcgr4tm1.1Rav
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:167375
|
\Fcmrtm1Ohno/\Fcmrtm1Ohno
(B6.129-Fcmrtm1Ohno)
|
increased anti-chromatin antibody level
|
J:190117
|
increased anti-double stranded DNA antibody level
|
J:190117
|
\Fcrlbtm1Pdb/\Fcrlbtm1Pdb
(B6.129-Fcrlbtm1Pdb)
|
increased anti-nuclear antigen antibody level
|
J:165408
|
\Fen1tm3.1Bhsh/\Fen1+
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
\Fen1tm3.1Bhsh/\Fen1tm3.1Bhsh
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
\Ffar2tm1Dgen/\Ffar2tm1Dgen
(involves: C57BL/6)
|
increased susceptibility to induced arthritis
|
J:153951
|
\Fgl1tm1b(EUCOMM)Hmgu/\Fgl1tm1b(EUCOMM)Hmgu
(involves: BALB/cJ * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:269578
|
\Flicrem1Doi/\Flicrem1Doi
(NOD/ShiLtDoi-Flicrem1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:241346
|
\Foxo1tm1Flv/\Foxo1tm1Flv \Tg(Cd4-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased anti-double stranded DNA antibody level
|
J:147057
|
increased anti-nuclear antigen antibody level
|
J:147057
|
\Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
increased autoantibody level
|
J:140085
|
\Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to autoimmune disorder
|
J:82560
|
\Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
\Foxp3tm1.1Ayr/\Foxp3tm1.1Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
\Foxp3tm1Ayr/Y \Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to autoimmune disorder
|
J:97029
|
\Foxp3tm1Kuch/? \Il6tm1Kopf/\Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123352
|
\Foxp3tm2.1(EGFP/cre)Shori/Y \Pdcd1tm1Hon/\Pdcd1tm1Hon
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:234397
|
\Foxp3tm2Flv/Y
(involves: C57BL/6)
|
increased autoantibody level
|
J:118631
|
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3+ \Gpr174tm1Cys/\Gpr174+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3tm3(HBEGF/GFP)Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
\Foxp3tm4(YFP/icre)Ayr/Y \Zfp91tm1Smoc/\Zfp91tm1Smoc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:306129
|
\Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr \Ikzf4tm1Djr/\Ikzf4tm1Djr
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:294549
|
\Foxp3tm8Ayr/Y
(B6.129-Foxp3tm8Ayr)
|
autoimmune response
|
J:157377
|
\Fpr2tm1Rjf/\Fpr2tm1Rjf
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:159658
|
\Fyntm1Yik/\Fyntm1Yik
(involves: C57BL/6 * CBA)
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
\Gabrb3tm2.1Geh/\Gabrb3tm2.1Geh \Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
\Gadd45atm1Ajf/\Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
\Gadd45btm1Flv/\Gadd45btm1Flv
(B6.129S6-Gadd45btm1Flv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:118837
|
\Gadd45btm1Flv/\Gadd45btm1Flv \Gadd45gtm1Flv/\Gadd45gtm1Flv
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:118837
|
increased anti-histone antibody level
|
J:118837
|
\Gata1tm6Sho/\Gata1tm6Sho
(C.129S1-Gata1tm6Sho)
|
autoimmune response
|
J:182213
|
\Gcc2em1Cya/\Gcc2em1Cya
(C57BL/6J-Gcc2em1Cya)
|
increased autoantibody level
|
J:346915
|
\Ghrtm1Jjk/\Ghrtm1Jjk
(involves: 129P2/OlaHsd * BALB/c)
|
decreased susceptibility to autoimmune diabetes
|
J:59132
|
\Ghrhtm1Salv/\Ghrhtm1Salv
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177054
|
\Ghrhrlit/\Ghrhrlit
(C57BL/6J-Ghrhrlit)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85381
|
\Gm614tm1.1Cya/\Gm614tm1.1Cya \Ighg1tm1(cre)Cgn/\Ighg1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
decreased susceptibility to systemic lupus erythematosus
|
J:307345
|
\Gna12tm1Citb/\Gna12tm1Citb \Gna13tm2.1Soff/\Gna13tm2.1Soff \Tg(Lck-cre)548Jxm/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased susceptibility to autoimmune diabetes
|
J:149560
|
\Gpr132tm1Witt/\Gpr132tm1Witt
(involves: 129X1/SvJ * BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:69473
|
\Gpr174tm1Cys/Y
(B6.129-Gpr174tm1Cys)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
\Gpr174tm1Cys/\Gpr174+
(B6.129-Gpr174tm1Cys)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
\Gpsm3Gt(IST12408A1)Tigm/\Gpsm3Gt(IST12408A1)Tigm
(involves: C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:193270
|
\Gpx7tm1Whle/\Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:193993
|
\Grk6tm1.1Mca/\Grk6tm1.1Mca
(B6.129S4-Grk6tm1.1Mca)
|
increased anti-double stranded DNA antibody level
|
J:225063
|
\Gt(ROSA)26Sortm1(DTA)Jpmb/\Gt(ROSA)26Sor+ \Tg(Plp1-cre/ERT)3Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
autoimmune response
|
J:234435
|
\Gt(ROSA)26Sortm1(Ptpn22*)Draw/\Gt(ROSA)26Sor+ \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased autoantibody level
|
J:201448
|
\Gt(ROSA)26Sortm2.1(Cd74/MOG)Awai/\Gt(ROSA)26Sor+
(involves: C57BL/6 * BALB/cJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
\Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/\Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky \Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
increased anti-double stranded DNA antibody level
|
J:133215
|
increased anti-single stranded DNA antibody level
|
J:133215
|
\Gvhd4DBA/2J/\Gvhd4DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
\Gvhd4DBA/2J/\Gvhd4DBA/2J \Gvhd5DBA/2J/\Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
\Gvhd5DBA/2J/\Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Rag1tm1Mom/\Rag1tm1Mom \Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
increased autoantibody level
|
J:113267
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
autoimmune response
|
J:87013,
J:86540
|
decreased susceptibility to autoimmune disorder
|
J:87013
|
increased autoantibody level
|
J:113267
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/\Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)
|
increased autoantibody level
|
J:113509
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(HLA-DRB1)31Dmz/0 \Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
increased susceptibility to autoimmune diabetes
|
J:59245
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)
|
increased susceptibility to autoimmune diabetes
|
J:68641
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)70Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)
|
increased autoantibody level
|
J:88055
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)73Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
|
increased autoantibody level
|
J:88055
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(HLA-DRB1)31Dmz/0 \Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru \Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
\H2-Ab1b-tm1Wug/\H2-Ab1b-tm1Wug
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
\H2-Ab1b-tm1Wug/\H2-Ab1b-tm1Wug \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
\H2-Ab1bm12/\H2-Ab1bm12
(B6(C)-H2-Ab1bm12/KhEgJ)
|
decreased susceptibility to autoimmune disorder
|
J:100123
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:100213
|
\H2-Ab1bm12/\H2-Ab1bm12
(NZB.B6(C)-H2-Ab1bm12)
|
autoimmune response
|
J:4554
|
increased anti-double stranded DNA antibody level
|
J:104189
|
increased anti-erythrocyte antigen antibody level
|
J:4554
|
increased anti-single stranded DNA antibody level
|
J:104189
|
\H2-Ab1g7-em1Dvs/\H2-Ab1g7-em1Dvs \H2-D1b-em5Dvs/\H2-D1b-em5Dvs \H2-K1d-em1Dvs/\H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-Ab1g7-em1Dvs H2-D1em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em1Dvs/\H2-D1b-em1Dvs
(NOD/ShiLtDvs-H2-D1b-em1Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em2Dvs/\H2-D1b-em2Dvs
(NOD/ShiLtDvs-H2-D1b-em2Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em3Dvs/\H2-D1b-em3Dvs
(NOD/ShiLtDvs-H2-D1b-em3Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em4Dvs/\H2-D1b-em4Dvs
(NOD/ShiLtDvs-H2-D1b-em4Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs \H2-K1d-em1Dvs/\H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs \H2-K1d-em1Dvs/\H2-K1d-em1Dvs \Tg(HLA-A/H2-D/B2M)1Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs \H2-K1d-em1Dvs/\H2-K1d-em1Dvs \Tg(HLA-B39/H2-D/B2m)2Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe \H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe X/\Yaa
(BXSB.129P2(B6)-H2-K1b-tm1Bpe H2-D1b-tm1Bpe/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\H2-DMatm1Luc/\H2-DMatm1Luc
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
\H2-DMatm1Luc/\H2-DMatm1Luc
(B6.129S4-H2-Dmatm1Luc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
\H2-K1d-em4Dvs/\H2-K1d-em4Dvs
(NOD/ShiLtDvs-H2-K1d-em4Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-K1d-em5Dvs/\H2-K1d-em5Dvs
(NOD/ShiLtDvs-H2-K1d-em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-K1d-em7Dvs/\H2-K1d-em7Dvs
(NOD/ShiLtDvs-H2-K1d-em7Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
\H2-T23tm1Cant/\H2-T23tm1Cant
(involves: 129S6/SvEvTac * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89808
|
\H2-T23tm2Cant/\H2-T23tm2Cant
(B6.129S6-H2-T23tm2Cant)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
\H2-T23tm2Cant/\H2-T23tm2Cant \Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: 129S6/SvEvTac)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
\H2-T23tm3Cant/\H2-T23tm3Cant
(B6.129S6-H2-T23tm3Cant)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
\H2b/\H2b
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2b/\H2d
((C57BL/6 x DBA/2)F1)
|
increased autoantibody level
|
J:106141
|
\H2b/\H2g7
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2b/\H2g7 \Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
rheumatoid arthritis
|
J:36815,
J:275827
|
\H2d/\H2d
(DBA/2)
|
increased autoantibody level
|
J:106141
|
\H2dlAb1-Ea/\H2dlAb1-Ea \Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
\H2dlAb1-Ea/\H2dlAb1-Ea \Tg(HLA-DRA,HLA-DRB5*0101)loKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
\H2g7/\H2g7 \Ins2tm1Jja/\Ins2tm1Jja \Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
\H2g7/\H2g7 \Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
\H2g7/\H2g7 \Tg(Ins2-Vtcn1)#Xxz/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: C57BL/6 * NOD * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:177612
|
\H2g7/\H2g7 \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:167508
|
\H2g7/\H2g7 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
\H2g7/\H2g7 \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
\H2g7/\H2q \Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
\H2h2/\H2g7
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2h2/\H2h2
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2h4/\H2g7
(NOD.Cg-H2h4)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2h4/\H2h4
(NOD.Cg-H2h4)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2i5/\H2g7
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2i5/\H2i5
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2i7/\H2g7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2i7/\H2i7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2k/\H2g7
(NOD.Cg-H2k)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
\H2k/\H2k
(NOD.Cg-H2k)
|
increased susceptibility to autoimmune diabetes
|
J:14178
|
\H2q/? \Ncf1m1J/\Ncf1m1J
(B6.Cg-Ncf1m1J H2q)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to induced arthritis
|
J:92437
|
rheumatoid arthritis
|
J:92437
|
\H2q/\H2q \Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
\H2u/\H2u \Rag1tm1Mom/\Rag1tm1Mom \Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
\H2u/\H2u \Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:19795
|
\H2u/\H2u \Tg(TCRA)B1Jg/? \Tg(TCRB)C14Jg/?
(involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)
|
increased autoantibody level
|
J:92991
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92991
|
\Havcr1tm1Kuch/\Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch)
|
autoimmune response
|
J:186484
|
increased anti-double stranded DNA antibody level
|
J:186484
|
\Hc0/\Hc0 \Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
decreased susceptibility to induced arthritis
|
J:134111
|
\Hc1/? \Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
\Hcsttm1.1Dnax/\Hcsttm1.1Dnax
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148086
|
\Hif1atm3Rsjo/\Hif1atm3Rsjo \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to induced arthritis
|
J:107682
|
\Hmox1tm1.1Gkl/\Hmox1tm1.1Gkl \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148498
|
\HrUSP/\HrUSP
(either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))
|
increased susceptibility to autoimmune disorder
|
J:21316
|
\Hrh3Eae8-r/?
(B10.S-H2s/SgMcdJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
\Hrh3Eae8-r/\Hrh3Eae8-r
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Hrh3Eae8-s/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
\Hrh3tm1Twl/\Hrh3tm1Twl
(B6.129X1-Hrh3tm1Twl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:122269
|
\Hspa13tm1.1Smoc/\Hspa13tm1.1Smoc \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6)
|
decreased autoantibody level
|
J:303927
|
\Ica1tm1Mdos/\Ica1tm1Mdos
(NOD.129-Ica1tm1Mdos)
|
decreased susceptibility to autoimmune diabetes
|
J:83526
|
\Icam1tm1Jcgr/\Icam1tm1Jcgr \Tg(INS-Il10)#Sar/0
(NOD.Cg-Icam1tm1Jcgr Tg(INS-Il10)#Sar)
|
decreased susceptibility to autoimmune diabetes
|
J:66103
|
\Icostm1Flv/\Icostm1Flv
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87123
|
\Icostm1Flv/\Icostm1Flv
(NOD.129S1-Icostm1Flv)
|
decreased anti-insulin autoantibody level
|
J:131529
|
decreased autoantibody level
|
J:131529
|
decreased susceptibility to autoimmune diabetes
|
J:131529
|
\Id3tm1Zhu/\Id3tm1Zhu
(involves: 129S4/SvJaeSor)
|
increased autoantibody level
|
J:93916
|
\Idd3A/J/\Idd3A/J
(NOD.A-Idd3A/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
\Idd3C57BL/6/\Idd3C57BL/6
(NOD.B6-Idd3C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
\Idd3CAST/EiJ/\Idd3CAST/EiJ
(NOD.CAST-Idd3CAST/EiJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
\Idd3CZECHI/EiJ/\Idd3CZECHI/EiJ
(NOD.CZECH-Idd3CZECHI/EiJ)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
\Idd3SWR/J/\Idd3SWR/J
(NOD.SWR-Idd3SWR/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
\Idd4.3C57L/\Idd4.3C57L
(involves: C57L/J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:118951
|
\Idd6.1C3H/HeJ/\Idd6.1C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
\Idd6.2C3H/HeJ/\Idd6.2C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
\Idd6.3C3H/HeJ/\Idd6.3C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
\Ifih1Rgsc422/\Ifih1+
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
autoimmune response
|
J:209917
|
increased anti-double stranded DNA antibody level
|
J:209917
|
increased anti-nuclear antigen antibody level
|
J:209917
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
\Ifih1Rgsc422/\Ifih1Rgsc422
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
\Ifnb1tm1Tl/\Ifnb1tm1Tl
(B10.129P2-Ifnb1tm1Tl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83021
|
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.129S7-Ifngtm1Ts)
|
abnormal susceptibility to autoimmune disorder
|
J:33427
|
decreased susceptibility to autoimmune diabetes
|
J:95105
|
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.Cg-Ifngtm1Ts Prkdcscid)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.129S7(B6)-Ifngtm1Ts/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
\Ifngtm1Ts/\Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34161
|
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased susceptibility to autoimmune disorder
|
J:39600
|
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)
|
decreased susceptibility to autoimmune disorder
|
J:119207
|
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:38363
|
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:53577
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * DBA/1OlaHsd)
|
increased susceptibility to induced arthritis
|
J:40634
|
\Ifngr2tm1Pbro/\Ifngr2tm1Pbro
(NOD.129S1-Ifngr2tm1Pbro)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
\Igh-7tm1Led/\Igh-7tm1Led \Lyntm1Ard/\Lyntm1Ard
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
\Igh-Jtm1(CB20)Riho/\Igh-J+
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
\Igh-Jtm1(CB20)Riho/\Igh-Jtm1(CB20)Riho
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
\Igh-Jtm1Aigl/\Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
\Igh-Jtm1Aigl/\Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
\Igh-Jtm1Aigl/\Igh-J+ \Mogtm1Dpd/\Mogtm1Dpd \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
\Igh-Jtm1Aigl/\Igh-J+ \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
\Igh-Jtm1Aigl/\Igh-Jtm1Aigl \Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(B6.129P2-Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
\Igh-Jtm3(3H9-VDJ*)Mwg/\Igh-Jtm3(3H9-VDJ*)Mwg
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
\Ightm1(Ighppc1-5)Cche/\Igh+
(B6.Cg-Ightm1(Ighppc1-5)Cche)
|
increased autoantibody level
|
J:138356
|
\Ightm2.1Hws/\Ightm2.1Hws
(involves: BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:142069
|
\Ighg1em1Wliu/\Ighg1em1Wliu
(C57BL/6-Ighg1em1Wliu)
|
increased anti-double stranded DNA antibody level
|
J:266937
|
increased anti-nuclear antigen antibody level
|
J:266937
|
increased autoantibody level
|
J:266937
|
\Ighmtm1Cgn/\Ighm+
(NOD.129S2-Ighmtm1Cgn)
|
increased susceptibility to autoimmune diabetes
|
J:37287
|
\Ighmtm1Cgn/\Ighm+ \Tg(Igh-6/Igh-V125)2Jwt/0 \Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
\Ighmtm1Cgn/\Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn)
|
decreased susceptibility to autoimmune diabetes
|
J:37287
|
\Ighmtm1Cgn/\Ighmtm1Cgn
(involves: 129S2/SvPas)
|
increased susceptibility to induced arthritis
|
J:157619
|
\Ighmtm1Cgn/\Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
\Ighmtm1Cgn/\Ighmtm1Cgn \Tg(Igh-VB1-8/Igh-6m)1Mjsk/?
(NODCaj.Cg-Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)
|
increased susceptibility to autoimmune diabetes
|
J:93190
|
\Ighmtm1Cgn/\Ighmtm1Cgn \Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
\Ighmtm1Cgn/\Ighmtm1Cgn X/\Yaa
(BXSB.129S2(B6)-Ighmtm1Cgn/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:206236
|
\Ighmtm1Msn/\Ighmtm1Msn
(involves: 129S/SvEv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:111817
|
increased autoantibody level
|
J:111817
|
\Igktm1Dhu/\Igktm1Dhu \Tg(H2-Ea-HA)HACIIAjca/0 \Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0
(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
|
decreased susceptibility to autoimmune disorder
|
J:209872
|
\Igkrstm1Nemz/\Igkrstm1Nemz \Tg(BCL2)22Wehi/?
(involves: 129 * C57BL)
|
increased anti-double stranded DNA antibody level
|
J:132125
|
\Ikzf3tm1Kge/\Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
autoimmune response
|
J:81805
|
increased anti-double stranded DNA antibody level
|
J:81805
|
increased anti-histone antibody level
|
J:81805
|
increased anti-nuclear antigen antibody level
|
J:81805
|
increased anti-single stranded DNA antibody level
|
J:81805
|
increased autoantibody level
|
J:81805,
J:50626
|
\Ikzf4tm1.1Etms/\Ikzf4tm1.1Etms
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:295208
|
\Il1atm1Yiw/\Il1atm1Yiw \Il1btm1Yiw/\Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165513
|
\Il1btm1Lvp/\Il1btm1Lvp
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:67001
|
\Il1r1em1Qizh/\Il1r1em1Qizh
(C57BL/6-Il1r1em1Qizh)
|
increased susceptibility to induced arthritis
|
J:338375
|
\Il1r1tm1Imx/\Il1r1tm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
\Il1r1tm1Imx/\Il1r1tm1Imx
(B6.129S7-Il1r1tm1Imx/J)
|
increased susceptibility to induced arthritis
|
J:125570
|
\Il1r1tm1Imx/\Il1r1tm1Imx \Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
\Il1r1tm1Imx/\Il1r1tm1Imx \Vsig4tm1Gne/\Vsig4tm1Gne
(B6.Cg-Il1r1tm1Imx Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
\Il1r1tm1Roml/\Il1r1tm1Roml
(NOD.Cg-Il1r1tm1Roml)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
\Il1r1tm1Roml/\Il1r1tm1Roml
(involves: 129S1/Sv)
|
decreased susceptibility to induced arthritis
|
J:120707
|
\Il1r2tm1Yiw/\Il1r2tm1Yiw
(B6.129P2-Il1r2tm1Yiw)
|
increased susceptibility to induced arthritis
|
J:274653
|
\Il1rntm1.1Cga/\Il1rntm1.1Cga \Lyz2tm1(cre)Ifo/\Lyz2+
(D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo)
|
increased susceptibility to induced arthritis
|
J:162760
|
\Il1rntm1Nick/\Il1rntm1Nick
(involves: BALB/cAnNHsd)
|
rheumatoid arthritis
|
J:89034
|
\Il1rntm1Nick/\Il1rntm1Nick
(involves: BALB/cAnNHsd * C57BL/6)
|
rheumatoid arthritis
|
J:89034
|
\Il1rntm1Yiw/\Il1rntm1Yiw
(C.129-Il1rntm1Yiw)
|
rheumatoid arthritis
|
J:143719
|
\Il1rntm1Yiw/\Il1rntm1Yiw \Il17atm1Yiw/\Il17a+
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
\Il2tm1.1Flv/\Il2tm1.1Flv
(NOD/ShiLtJ-Il2tm1.1Flv)
|
abnormal susceptibility to autoimmune disorder
|
J:150823
|
\Il2tm1Hor/\Il2+
(NOD.129P2(B6)-Il2tm1Hor/DvsJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
\Il2tm1Hor/\Il2tm1Hor
(C.129P2-Il2tm1Hor)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:29799
|
\Il2tm1Hor/\Il2tm1Hor
(B6.129P2-Il2tm1Hor/J)
|
increased susceptibility to autoimmune disorder
|
J:113547
|
\Il2rbtm1Mak/\Il2rbtm1Mak
(either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))
|
increased anti-nuclear antigen antibody level
|
J:25940
|
increased susceptibility to autoimmune hemolytic anemia
|
J:25940
|
\Il2rbtm1Mak/\Il2rbtm1Mak
(B6.129-Il2rbtm1Mak)
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
\Il2rbtm1Mak/\Il2rbtm1Mak
(C.129-Il2rbtm1Mak)
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
\Il4tm1Cgn/\Il4tm1Cgn
(NOD.129P2-Il4tm1Cgn)
|
decreased susceptibility to autoimmune disorder
|
J:95105
|
increased susceptibility to autoimmune disorder
|
J:95105
|
\Il4tm1Cgn/\Il4tm1Cgn
(either: NOD.129-Il4tm1Cgn or (involves: 129 * NOD))
|
autoimmune response
|
J:85924
|
\Il4tm1Cgn/\Il4tm1Cgn \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:85924
|
\Il4tm1Kopf/\Il4tm1Kopf \Lyntm1Ard/\Lyntm1Ard
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
\Il4tm1Nnt/\Il4tm1Nnt
(involves: C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
\Il4tm2Nnt/\Il4tm2Nnt
(BALB/c-Il4tm2Nnt/J)
|
decreased susceptibility to autoimmune disorder
|
J:141937
|
\Il5ratm1Ktk/\Il5ratm1Ktk \Lyntm1Tya/\Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:91089
|
\Il6tm1Kopf/\Il6tm1Kopf
(B6.129S2-Il6tm1Kopf/J)
|
decreased susceptibility to induced arthritis
|
J:208213
|
\Il6sttm1Ern/\Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:142883
|
\Il6sttm1Thir/\Il6sttm1Thir
(involves: 129 * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:133059
|
increased anti-nuclear antigen antibody level
|
J:133059
|
increased anti-single stranded DNA antibody level
|
J:133059
|
increased autoantibody level
|
J:133059
|
rheumatoid arthritis
|
J:133059
|
\Il9rtm1Jcrd/\Il9rtm1Jcrd
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151907
|
\Il10raNZW/\Il10ra+
((NZB x NZW)F1)
|
increased anti-chromatin antibody level
|
J:102087
|
\Il10ratm1.1Tlg/\Il10ratm1.1Tlg \Tg(Cd4-cre)1Cwi/?
(B6.Cg-Tg(Cd4-cre)1Cwi Il10ratm1.1Tlg)
|
autoimmune response
|
J:189797
|
\Il12atm1Cab/\Il12atm1Cab \Il23atm1.1Thak/\Il23atm1.1Thak
(B6.Cg-Il12atm1Cab Il23atm1.1Thak)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
\Il12rb2tm1Jm/\Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
increased anti-nuclear antigen antibody level
|
J:106805
|
\Il13tm1.1Anjm/\Il13tm1.1Anjm
(C.129P2-Il13tm1.1Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:141937,
J:91403
|
\Il13tm2Anjm/\Il13tm2Anjm
(B6.129P2-Il13tm2Anjm)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:131969
|
\Il15tm1Imx/\Il15tm1Imx X/\Yaa
(BXSB.B6-Il15tm1Imx/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\Il17atm1Cdon/\Il17atm1Cdon
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
\Il17atm1Yiw/\Il17atm1Yiw \Il1rntm1Yiw/\Il1rntm1Yiw
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
\Il17atm1Yiw/\Il17atm1Yiw \Il17ftm1Yiw/\Il17ftm1Yiw \Il1rntm1Yiw/\Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
\Il17atm1Yiw/\Il17atm1Yiw \Tg(CD2-Rorc)#Staka/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:230700
|
\Il17ctm1.1Cdon/\Il17ctm1.1Cdon
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
\Il17ftm1Cdon/\Il17ftm1Cdon
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
\Il17ftm1Yiw/\Il17ftm1Yiw \Il1rntm1Yiw/\Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
\Il17rctm1Lex/\Il17rctm1Lex
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:159874
|
\Il21tm1Lex/\Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123351
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
\Il21rtm1Kopf/\Il21rtm1Kopf
(B6.129-Il21rtm1Kopf)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
\Il21rtm1Wjl/\Il21rtm1Wjl
(NOD.Cg-Il21rtm1Wjl)
|
decreased susceptibility to autoimmune diabetes
|
J:139075
|
\Il21rtm1Wjl/\Il21rtm1Wjl X/\Yaa
(BXSB.129(Cg)-Il21rtm1Wjl/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:144484
|
\Il23atm1.1Thak/\Il23atm1.1Thak
(C57BL/6-Il23atm1.1Thak)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
\Il23atm1Dnax/\Il23atm1Dnax
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:95542
|
\Il23rtm1Kuch/\Il23rtm1Kuch
(C57BL/6-Il23rtm1Kuch)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148248
|
\Il25tm1Dart/\Il25tm1Dart
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:125296
|
\Il27tm1Cua/\Il27tm1Cua
(C57BL/6-Il27tm1Cua)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:147706
|
\Il27ratm1Mak/\Il27ratm1Mak
(B6.129P2-Il27ratm1Mak)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116610
|
\Il27ratm1Mak/\Il27ratm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:151552
|
\Imh1NZB/\Imh1NZB
(involves: NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:26266
|
\Imh1NZB/\Imh1NZW
(involves: NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:22353
|
\Inpp5dtm1Rav/\Inpp5dtm1Rav \Cd79atm1(cre)Reth/\Cd79a+ \Tg(IghAb36-65)1Wys/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
increased autoantibody level
|
J:178833
|
\Ins1tm1Jja/\Ins1tm1Jja
(NOD.129S2-Ins1tm1Jja)
|
decreased susceptibility to autoimmune diabetes
|
J:85309
|
\Ins1tm1Jja/\Ins1tm1Jja \Ins2tm1Jja/\Ins2tm1Jja \Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell)
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
\Ins1tm1Jja/\Ins1tm1Jja \Ins2tm1Jja/\Ins2tm1Jja \Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
decreased anti-insulin autoantibody level
|
J:98583
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
\Ins1tm1Jja/\Ins1tm1Jja \Ins2tm1Mnt/\Ins2tm1Mnt \Tg(Aire-cre)1Mnt/0
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased anti-insulin autoantibody level
|
J:152798
|
\Ins1tm1Jja/\Ins1tm1Jja \Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
\Ins1tm1Jja/\Ins1tm1Jja \Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
\Ins2C95S/\Ins2+
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
\Ins2C95S/\Ins2C95S
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
\Ins2tm1Jja/\Ins2tm1Jja
(NOD.129S2-Ins2tm1Jja)
|
increased anti-insulin autoantibody level
|
J:85309
|
\Ins2tm1Jja/\Ins2tm1Jja \Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
increased anti-insulin autoantibody level
|
J:98583
|
\Irak1tm1Jth/Y
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
\Irak1tm1Jth/\Irak1tm1Jth
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
\Irak3tm1Flv/\Irak3tm1Flv
(NOD.129S1(B6)-Irak3tm1Flv)
|
increased anti-insulin autoantibody level
|
J:229884
|
increased susceptibility to autoimmune diabetes
|
J:229884
|
\Irf1tm1Cwe/\Irf1tm1Cwe
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:43086
|
\Irf1tm1Cwe/\Irf1tm1Cwe
(involves: 129)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:84367
|
\Irs1tm1Mfw/\Irs1tm1Mfw \Irs2tm2Mfw/\Irs2tm2Mfw \Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137845
|
\Irs1tm2Tka/\Irs1tm2Tka \Irs2tm2Tka/\Irs2tm2Tka \Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137846
|
\Itgavtm2Hyn/\Itgavtm2.1Hyn \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)
|
increased autoantibody level
|
J:125508
|
\Itgavtm2Hyn/\Itgavtm2.1Hyn \Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
increased autoantibody level
|
J:125508
|
\Itgaxtm1Bll/\Itgaxtm1Bll
(B6.129S7-Itgaxtm1Bll)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:122187
|
\Itgb2tm1Bay/\Itgb2tm1Bay \Psrs1PL/J/\Psrs1PL/J
(B6.Cg-(D10Mit126-D10Mit38) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
\Itgb2tm1Bay/\Itgb2tm1Bay \Psrs1PL/J/\Psrs1PL/J
(B6.Cg-(D10Mit75-D10Mit271) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
\Jak1M1Mhda/\Jak1+
(C3HeB/FeJ-Jak1M1Mhda)
|
increased anti-nuclear antigen antibody level
|
J:199153
|
\Junbtm3Wag/\Junbtm3Wag \Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
increased anti-histone antibody level
|
J:155575
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
\KitW-sh/\KitW-sh \Lyntm1Ard/\Lyntm1Ard
(involves: 101 * 129P2/OlaHsd * C3H/HeH)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
\KitW/\KitW-v
((WB KitW x B6.Cg-KitW-v)F1)
|
decreased susceptibility to induced arthritis
|
J:178942
|
\Ksr1tm1Shaw/\Ksr1tm1Shaw
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:140520
|
\Lag3tm1Daav/\Lag3+ \Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
\Lag3tm1Daav/\Lag3tm1Daav \Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
\Laq1MRL/\Laq1MRL
(involves: C57BL/6 * MRL)
|
increased susceptibility to autoimmune disorder
|
J:45708
|
\Lat2tm1Mal/\Lat2tm1Mal
(B6.129S2-Lat2tm1Mal)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
\Lat2tm1Mal/\Lat2tm1Mal \Lime1tm1.1Mal/\Lime1tm1.1Mal
(involves: 129 * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
\Lat2tm1Wz/\Lat2tm1Wz
(B6.Cg-Lat2tm1Wz)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased autoantibody level
|
J:116157
|
\Lat2tm2Wz/\Lat2tm2Wz \Tg(Lck-cre)548Jxm/0
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
\Lattm1.1Lov/\Lattm1.1Lov
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased anti-nuclear antigen antibody level
|
J:77099
|
increased autoantibody level
|
J:77099
|
\Lattm1.1Lov/\Lattm1.1Lov \Lat2tm1Wz/\Lat2tm1Wz
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
\Lattm1.1Mal/\Lattm1.1Mal
(involves: 129S2/SvPas)
|
increased anti-chromatin antibody level
|
J:125722
|
increased anti-erythrocyte antigen antibody level
|
J:125722
|
increased anti-nuclear antigen antibody level
|
J:125722
|
increased susceptibility to autoimmune hemolytic anemia
|
J:125722
|
\Lbric-J/\Lbr+
((NZW/LacJ x C57BL/6J-Lbric-J/J)F1)
|
increased anti-chromatin antibody level
|
J:234168
|
increased anti-nuclear antigen antibody level
|
J:234168
|
increased autoantibody level
|
J:234168
|
increased susceptibility to systemic lupus erythematosus
|
J:234168
|
\Lbw2NZB/BlScr/\Lbw2NZB/BlScr
(involves: NZB * NZW)
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
\Lbw2NZB/BlScr/\Lbw2NZW/LacScr
(involves: NZB * NZW)
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
\Lbw2NZW/LacScr/\Lbw2NZW/LacScr
(involves: NZB * NZW)
|
decreased autoantibody level
|
J:98150
|
\Lbw5NZW/LacScr/\Lbw5NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
\Lbw5NZW/LacScr/\Lbw5NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
\Lbw6NZW/LacScr/\Lbw6NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
\Lbw7NZB/BlScr/\Lbw7NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
\Lbw7NZB/BlScr/\Lbw7NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
\Lbw8NZB/BlScr/\Lbw8NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
\Lbw8NZB/BlScr/\Lbw8NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
\Lcp2twm/\Lcp2twm
(C57BL/6JSfdAnu-Lcp2twm/Anu)
|
autoimmune response
|
J:104190
|
\Lctlp1FVB/NJ/\Lctlp1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
\Lctlp2FVB/NJ/\Lctlp2FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
\Leprdb/\Leprdb
(involves: C57BLKS/J)
|
increased susceptibility to autoimmune diabetes
|
J:7005
|
\Lgals1tm1Rob/\Lgals1tm1Rob
(involves: 129S/SvEv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:123416
|
\Lgals9tm1Glp/\Lgals9tm1Glp
(B6.129S6-Lgals9tm1Glp)
|
increased susceptibility to induced arthritis
|
J:132889
|
\Lig4tm2.1Fwa/\Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased anti-chromatin antibody level
|
J:157574
|
increased anti-double stranded DNA antibody level
|
J:157574
|
\ll/\ll X/\Yaa
(BXSB/MpJScr-ll)
|
decreased anti-nuclear antigen antibody level
|
J:10973
|
decreased susceptibility to autoimmune disorder
|
J:10973
|
\Lmb1C57BL/6Scr/\Lmb1C57BL/6Scr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
\Lmb1C57BL/6Scr/\Lmb1MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
\Lmb2C57BL/6Scr/\Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
\Lmb2MRL/MpScr/\Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
\Lrch1em1Hwa/\Lrch1em1Hwa
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
\Lrp3em1Cya/\Lrp3em1Cya
(C57BL/6N-Lrp3em1Cya/Cya)
|
increased susceptibility to induced arthritis
|
J:345338
|
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased susceptibility to induced arthritis
|
J:115034
|
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased susceptibility to induced arthritis
|
J:115034
|
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:108446
|
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor)
|
decreased susceptibility to induced arthritis
|
J:131779
|
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))
|
decreased susceptibility to induced arthritis
|
J:163271
|
\Ltb4r2tm1Bodd/\Ltb4r2tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:163271
|
\Ltc4stm1Blam/\Ltc4stm1Blam
(C.129S7-Ltc4stm1Blam)
|
autoimmune response
|
J:182213
|
\Lxw1BXSB/Scr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
\Lxw3NZW/LacScr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
\Lynmld4/\Lynmld4
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:144799
|
\Lyntm1.1Calo/\Lyntm1.1Calo \Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased autoantibody level
|
J:200745
|
\Lyntm1Ard/\Lyntm1Ard
(involves: 129P2/OlaHsd)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
\Lyntm1Ard/\Lyntm1Ard
(B6.129P2-Lyntm1Ard)
|
increased anti-double stranded DNA antibody level
|
J:144799
|
increased anti-nuclear antigen antibody level
|
J:144799
|
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJae)
|
increased anti-double stranded DNA antibody level
|
J:42037
|
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJaeSor)
|
increased anti-double stranded DNA antibody level
|
J:146161
|
increased autoantibody level
|
J:200745
|
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:71174
|
increased susceptibility to systemic lupus erythematosus
|
J:71174
|
\Lyntm1Tya/\Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:29751
|
\Lynweeb/\Lynweeb
(C57BL/6-Lynweeb)
|
increased anti-double stranded DNA antibody level
|
J:146161
|
\Lyz2tm1(cre)Ifo/\Lyz2tm1(cre)Ifo \Nrrostm1Wouy/\Nrrostm1Wouy
(involves: 129P2/OlaHsd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
\Map4k1tm1Tht/\Map4k1tm1Tht
(B6.129S7-Map4k1tm1Tht)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:116613
|
\Map4k3Gt(RRO270)Byg/\Map4k3Gt(RRO270)Byg
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177642
|
\Mapk3tm1Gela/\Mapk3tm1Gela
(either: 129(Cg)-Mapk3tm1Gela or B6.129-Mapk3tm1Gela)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:107504
|
\Mapk11tm1Jda/\Mapk11tm1Jda \Mapk14tm1Jda/\Mapk14tm1Jda
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165966
|
decreased susceptibility to induced arthritis
|
J:165966
|
\Mbpshi/\Mbpshi
(involves: BALB/c * C3HeB/Fe * SWV)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:48412
|
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1+
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1Tg(HLA-A2.1)1Enge
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
\Mertktm1Gkm/\Mertktm1Gkm
(NOD.129P2-Mertktm1Gkm)
|
decreased susceptibility to autoimmune diabetes
|
J:147153
|
\Mertktm1Gkm/\Mertktm1Gkm
(B6.129P2-Mertktm1Gkm)
|
decreased autoantibody level
|
J:136377
|
\Mex3btm1.1Mbld/\Mex3btm1.1Mbld \Plekha5Tg(AMH-cre)1Flor/\Plekha5+
(involves: C57BL/6 * SJL)
|
increased anti-sperm antibody level
|
J:213588
|
\Mfge8tm1Osa/\Mfge8tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:225063
|
\Mfge8tm1Osa/\Mfge8tm1Osa \Timd4tm1Osa/\Timd4tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:187181
|
increased anti-nuclear antigen antibody level
|
J:187181
|
\Mir125atm1Smoc/\Mir125atm1Smoc
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
\Mir140tm1.1Asah/\Mir140tm1.1Asah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased susceptibility to induced arthritis
|
J:160358
|
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl \Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:266124
|
\Mir146tm2.1Bal/\Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased anti-double stranded DNA antibody level
|
J:173671
|
\Mir155tm1.1Rsky/\Mir155tm1.1Rsky
(B6.Cg-Mir155tm1Rsky/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
\Mir204tm1.2Dic/\Mir204tm1.2Dic \Mir211tm1.2Dic/\Mir211tm1.2Dic
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:345335
|
\Mir210tm1.1Wtsi/\Mir210tm1.1Wtsi
(involves: C57BL/6J * C57BL/6N)
|
increased anti-chromatin antibody level
|
J:205868
|
increased anti-double stranded DNA antibody level
|
J:205868
|
increased anti-nuclear antigen antibody level
|
J:205868
|
\Mirc33tm1.1Cwh/\Mirc33tm1.1Cwh
(involves: 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189763
|
\Mmdtm1Beij/\Mmdtm1Beij
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:304637
|
\Mmp2tm1Ito/\Mmp2tm1Ito
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94099
|
\Mmp9tm1Arnd/\Mmp9tm1Arnd
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:58833
|
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(C3N.129S6-Mmp9tm1Tvu)
|
decreased susceptibility to induced arthritis
|
J:150311
|
\Mogtm1(cre)Gkl/\Mogtm1(cre)Gkl \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
\Mogtm1Dpd/\Mogtm1Dpd
(B6.129S2-Mogtm1Dpd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85155
|
\Mogtm1Dpd/\Mogtm1Dpd \Rag2tm1Cgn/\Rag2tm1Cgn \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
\Mogtm1Dpd/\Mogtm1Dpd \Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
\Mogtm1Dpd/\Mogtm1Dpd \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
\Mogtm1Reid/\Mogtm1Reid
(B6.129S1/Sv-Mogtm1Reid)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
\Mogtm1Reid/\Mogtm1Reid
(129/Sv-Mogtm1Reid)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
\Mpgtm1Lds/\Mpgtm1Lds
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:118148
|
decreased susceptibility to autoimmune diabetes
|
J:118148
|
\Mpotm1Lus/\Mpotm1Lus
(involves: 129X1/SvJ * C57BL/6J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:102965
|
\Mpztm1Msch/\Mpz+
(B6.129S7-Mpztm1Msch)
|
autoimmune response
|
J:59319
|
\Mr1tm1Gfn/\Mr1tm1Gfn
(B6.129P2-Mr1tm1Gfn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
\Mt1tm1Bri/\Mt1tm1Bri \Mt2tm1Bri/\Mt2tm1Bri
(involves: 129S7/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:103102
|
\mt-Nd2m1
(ALR/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:117602,
J:97969
|
\Mta2tm1.1Yzha/\Mta2tm1.1Yzha
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased anti-double stranded DNA antibody level
|
J:137101
|
increased autoantibody level
|
J:137101
|
increased susceptibility to systemic lupus erythematosus
|
J:137101
|
\Mtus1Gt(RRA048)Byg/\Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:212144
|
\Mtv7BALB/c/\Mtv7BALB/c
(involves: B10.Q * BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:27701
|
\Mtv7BALB/c/\Mtv7DBA/2
(involves: B10.Q * BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
\Mtv7DBA/2/\Mtv7DBA/2
(C.D2-Mtv7DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
\Muc19sld/\Muc19sld
(NFS/N-Muc19sld)
|
increased susceptibility to autoimmune disorder
|
J:216958,
J:20364
|
\Myd88tm1Aki/\Myd88tm1Aki
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
\Myd88tm1Aki/\Myd88tm1Aki
(C.129P2-Myd88tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
\Myd88tm1Aki/\Myd88tm1Aki \Tanktm1Aki/\Tanktm1Aki
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:151757
|
\Myl3tm1a(EUCOMM)Hmgu/\Myl3tm1a(EUCOMM)Hmgu \Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
increased susceptibility to induced arthritis
|
J:343166
|
\Nba4NZB/\Nba4NZB
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96263
|
increased anti-single stranded DNA antibody level
|
J:96060
|
\Nba4NZB/\Nba4SWR
(involves: NZB * SWR)
|
increased anti-histone antibody level
|
J:96263
|
\Nba10NZB/?
(involves: C57BL/6 * NZB * SB/Le)
|
increased anti-chromatin antibody level
|
J:95829
|
increased anti-double stranded DNA antibody level
|
J:95829
|
\Nba10NZB/\Nba10NZB \Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZB)
|
increased anti-chromatin antibody level
|
J:134128
|
increased anti-double stranded DNA antibody level
|
J:134128
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
\Nba10NZB/\Nba10NZB \Tlr7tm1Aki/Y X/\Yaa
(B6.Cg-Nba10NZB Tlr7tm1Aki Yaa)
|
increased anti-chromatin antibody level
|
J:137656
|
\Nba10NZB/\Nba10NZB X/\Yaa
(C57BL/6-Nba2 Yaa)
|
increased anti-chromatin antibody level
|
J:137656
|
increased anti-nuclear antigen antibody level
|
J:95829
|
increased autoantibody level
|
J:137656
|
increased susceptibility to autoimmune disorder
|
J:95829
|
\Nba12NZB/\Nba12NZB
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
\Nba12NZB/\Nba12SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
\Nbwa1NZB/?
(involves: BALB/c * NZB * NZW)
|
increased anti-chromatin antibody level
|
J:88464
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased anti-single stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
\Nbwa2NZB/?
(involves: BALB/c * NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
\Nbwa2NZW/?
(involves: BALB/c * NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
\Ncf2tm1b(EUCOMM)Wtsi/\Ncf2+
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
\Ncf2tm1b(EUCOMM)Wtsi/\Ncf2tm1b(EUCOMM)Wtsi
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
\Ndst2tm1Rls/\Ndst2tm1Rls
(B6.Cg-Ndst2tm1Rls)
|
decreased susceptibility to induced arthritis
|
J:142880
|
\Nek7M1Btlr/\Nek7M1Btlr
(C57BL/6J-Nek7M1Btlr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
\Nfatc1tm1.1Fbs/\Nfatc1tm1.1Fbs
(C57BL/6-Nfatc1tm1.1Fbs)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:305649
|
\Nfatc1tm1Rao/\Nfatc1tm1Rao \Cd79atm1(cre)Reth/\Cd79a+
(involves: BALB/c)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177319
|
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
|
increased anti-double stranded DNA antibody level
|
J:104016
|
increased anti-nuclear antigen antibody level
|
J:104016
|
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:150597
|
\Nfe2l2tm1Ywk/\Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk)
|
increased anti-double stranded DNA antibody level
|
J:165602
|
\Nfil3tm1.1Kubo/\Nfil3tm1.1Kubo
(B6.Cg-Nfil3tm1.1Kubo)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172134
|
\Nfkb1tm1Bal/\Nfkb1tm1Bal
(B6;129P-Nfkb1tm1Bal/J)
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
\Nfkb2Lym1/\Nfkb2Lym1
(involves: BALB/c)
|
autoimmune response
|
J:154812
|
\Nfkbiatm1.1Pjc/\Nfkbiatm1.1Pjc
(involves: C57BL/6)
|
autoimmune response
|
J:163686
|
increased anti-insulin autoantibody level
|
J:163686
|
increased anti-nuclear antigen antibody level
|
J:163686
|
\Nfkbibtm1Bal/\Nfkbibtm1Bal
(B6.129S1-Nfkbibtm1Bal)
|
decreased susceptibility to induced arthritis
|
J:163302
|
\Ngfrtm1Jae/\Ngfrtm1Jae
(B6.129S4-Ngfrtm1Jae)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112769
|
\Ninj1tm1Gto/\Ninj1+
(B6.129P2-Ninj1tm1Gto)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
\Ninj1tm1Gto/\Ninj1tm1Gto
(B6.129P2-Ninj1tm1Gto)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
\Nlrp3M6Btlr/\Nlrp3M6Btlr
(C57BL/6J-Nlrp3M6Btlr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
\Nlrp3tm1Wstr/\Nlrp3+
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:150053
|
\Nlrp3tm2Hhf/\Nlrp3tm2Hhf \Vsig4tm1Gne/\Vsig4tm1Gne
(B6.Cg-Nlrp3tm2Hhf Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
\Nlrp10tm1Seis/\Nlrp10tm1Seis
(B6.Cg-Nlrp10tm1Seis)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:183989
|
\Nod2tm1Flv/\Nod2tm1Flv
(C.129S1-Nod2tm1Flv)
|
decreased susceptibility to induced arthritis
|
J:178054
|
\Nos2tm1Mrl/\Nos2tm1Mrl
(involves: 129S7/SvEvBrd * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:46192
|
\Nr3c1tm2.1Gsc/\Nr3c1+
(B6.129P2-Nr3c1tm2.1Gsc)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
\Nr3c1tm2Gsc/\Nr3c1tm2Gsc \Tg(Lck-cre)I57Jxm/0
(B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
\Nrrostm1Lex/\Nrrostm1Lex
(B6.129S5-Nrrostm1Lex)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
\Nudt7em1Ejj/\Nudt7em1Ejj
(involves: C57BL/6N)
|
increased susceptibility to induced arthritis
|
J:266261
|
\Nwa2NZW/LacJ/\Nwa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
|
increased anti-histone antibody level
|
J:35434
|
increased anti-single stranded DNA antibody level
|
J:35434
|
\Otub1tm1c(EUCOMM)Hmgu/\Otub1tm1c(EUCOMM)Hmgu \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:280549
|
increased anti-nuclear antigen antibody level
|
J:280549
|
increased susceptibility to autoimmune disorder
|
J:280549
|
increased susceptibility to systemic lupus erythematosus
|
J:280549
|
\Paam1MRL/MpJ/\Paam1MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
\Paam2MRL/MpJ/\Paam2MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
\Padi2tm1Lex/\Padi2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
autoimmune response
|
J:190651
|
\Panx3tm1c(KOMP)Wtsi/\Panx3tm1c(KOMP)Wtsi \Tg(Col2a1-cre)1Star/0
(involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
\Panx3tm1d(KOMP)Wtsi/\Panx3tm1d(KOMP)Wtsi
(involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
\Pbat1BXSB/Slc/\Pbat1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Pbat1BXSB/Slc/\Pbat1NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Pbat2BXSB/Slc/\Pbat2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Pbat2BXSB/Slc/\Pbat2NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
\Pdcd1tm1.1Shr/\Pdcd1tm1.1Shr \Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
\Pdcd1tm1Hon/\Pdcd1tm1Hon
(C.129S2(B6)-Pdcd1tm1Hon)
|
increased autoantibody level
|
J:66979
|
\Pdcd1tm1Hon/\Pdcd1tm1Hon \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
\Pdcd1tm1Hon/\Pdcd1tm1Hon \Vsirtm1Lex/\Vsirtm1Lex \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
\Pdcd1tm1Llc/\Pdcd1tm1Llc
(involves: 129S5/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
\Pdcd1lg2tm3Shr/\Pdcd1lg2tm3Shr
(involves: C57BL/6 * NOD/MrkTac)
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
\Pdcd4tm1Yhcn/\Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
|
decreased susceptibility to autoimmune diabetes
|
J:120583
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:120583
|
\Pecam1tm1Mak/\Pecam1+
(D1.129P2-Pecam1tm1Mak)
|
increased susceptibility to induced arthritis
|
J:106275
|
\Pecam1tm1Mak/\Pecam1tm1Mak
(D1.129P2-Pecam1tm1Mak)
|
increased susceptibility to induced arthritis
|
J:106275
|
\Pgam1tm1.1Hiko/\Pgam1tm1.1Hiko \Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:293746
|
\Pgap3tm1.1Ymra/\Pgap3tm1.1Ymra
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:181221
|
\Pgap3tm1.1Ymra/\Pgap3tm1.1Ymra
(B6.Cg-Pgap3tm1.1Ymra)
|
increased anti-double stranded DNA antibody level
|
J:203443
|
increased anti-single stranded DNA antibody level
|
J:203443
|
\Pgia1BALB/cCrl/\Pgia1DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
increased susceptibility to autoimmune disorder
|
J:66460
|
\Pgia2BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia3DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia4BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia6BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia7BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia8DBA/2/\Pgia8DBA/2
(C.D2-(D15Mit12-D15Mit267))
|
decreased susceptibility to induced arthritis
|
J:137478
|
\Pgia8DBA/2/\Pgia8DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:137478
|
\Pgia9DBA/2/\Pgia9DBA/2
(C.D2-(D15Mit267-D15Mit41))
|
decreased susceptibility to induced arthritis
|
J:137478
|
\Pgia9DBA/2/\Pgia9DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:137478
|
\Pgia10BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia11BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
\Pgia13C3H/HeJCr/\Pgia13C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
\Pgia14C3H/HeJCr/\Pgia14C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
\Pgia15C3H/HeJCr/\Pgia15C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
\Pgia16C3H/HeJCr/\Pgia16C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:65424
|
\Pgia39DBA/2Crl/\Pgia39DBA/2Crl \Pgia6DBA/2Crl/\Pgia6DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
\Pgia39DBA/2Crl/\Pgia39DBA/2Crl \Pgia26BALB/cCrl/\Pgia26BALB/cCrl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
\Pgis1DBA/2/\Pgis1DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
\Pgis1DBA/2/\Pgis1DBA/2 \Pgis2BALB/c/\Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
\Pgis1DBA/2/\Pgis1DBA/2 \Pgis2BALB/c/\Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
\Pgis2BALB/c/\Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
\Pgis2BALB/c/\Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz
(C.129S-Pglyrp1tm1Rdz)
|
increased susceptibility to induced arthritis
|
J:178054
|
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz \Pglyrp2tm1Rdz/\Pglyrp2tm1Rdz
(C.129S-Pglyrp1tm1Rdz Pglyrp2tm1Rdz)
|
decreased susceptibility to induced arthritis
|
J:178054
|
\Pglyrp2tm1Rdz/\Pglyrp2tm1Rdz
(C.129S-Pglyrp2tm1Rdz)
|
decreased susceptibility to induced arthritis
|
J:178054
|
\Pik3c2aGt(OST288105)Lex/\Pik3c2aGt(OST288105)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:169710
|
\Pik3cdem1.1Pls/\Pik3cd+
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:282486
|
increased anti-nuclear antigen antibody level
|
J:282486
|
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
(B6.129S4-Pik3cdtm1Tnr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr \Pik3cgtm1Pngr/\Pik3cgtm1Pngr
(B6.129-Pik3cdtm1Tnr Pik3cgtm1Pngr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr
(B6.129P2-Pik3cgtm1Pngr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
\Pkn1tm1Kik/\Pkn1tm1Kik
(B6.129P2-Pkn1tm1Kik)
|
increased anti-double stranded DNA antibody level
|
J:193187
|
\Pla1aem1Appsc/\Pla1aem1Appsc
(C57BL/6J-Pla1aem1Appsc)
|
decreased susceptibility to induced arthritis
|
J:333902
|
\Pla2g4atm1Tksh/\Pla2g4atm1Tksh
(B6.129P2-Pla2g4atm1Tksh)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:107430
|
\Plautm1Mlg/\Plautm1Mlg
(B6.Cg-Plautm1Mlg)
|
decreased susceptibility to induced arthritis
|
J:75303
|
\Plcg1tm1Gcrp/\Plcg1tm1Rwen \Tg(Cd4-cre)1Cwi/0
(either: B6.Cg-Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))
|
increased anti-double stranded DNA antibody level
|
J:157757
|
\Plcg2tm1Jni/\Plcg2tm1Jni
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:157619
|
\Plcl2tm1Tta/\Plcl2tm1Tta
(involves: 129P2/OlaHsd)
|
increased anti-nuclear antigen antibody level
|
J:85960
|
\Pld4thss/\Pld4thss
(BALB/cJ-Pld4thss/GrsrJ)
|
increased anti-nuclear antigen antibody level
|
J:278304
|
\plt/\plt
(either: B6.DDD-plt or C.DDD-plt)
|
increased susceptibility to autoimmune disorder
|
J:110910
|
\Polbtm1.1Jbsw/\Polb+
(involves: 129/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:206872
|
\Polbtm1.1Jbsw/\Polbtm1.1Jbsw
(involves: 129/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:206872
|
increased susceptibility to systemic lupus erythematosus
|
J:206872
|
\Ppargtm1.1Gonz/\Ppargtm1.1Gonz \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
\Ppargtm1Tka/\Pparg+
(involves: C57BL/6 * CBA * ICR)
|
increased susceptibility to induced arthritis
|
J:58222
|
\Ppargtm2Rev/\Ppargtm2Rev \Tg(Cd4-cre)1Cwi/?
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:153358
|
\Prdm1tm1Clme/\Prdm1tm1Clme \Tg(Itgax-cre)1-1Reiz/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased anti-double stranded DNA antibody level
|
J:178876
|
increased anti-nuclear antigen antibody level
|
J:178876
|
increased autoantibody level
|
J:178876
|
\Prf1tm1Clrk/\Prf1tm1Clrk
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
\Prf1tm1Clrk/\Prf1tm1Clrk \Tg(INS-Il10)#Sar/0
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
\Prf1tm1Sdz/\Prf1+
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
\Prf1tm1Sdz/\Prf1tm1Sdz
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
\Prf1tm1Sdz/\Prf1tm1Sdz X/\Yaa
(BXSB.B6-Prf1tm1Sdz/Dcr)
|
autoimmune response
|
J:179430
|
\Prkcdtm1Kin/\Prkcdtm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-chromatin antibody level
|
J:76135
|
\Prkcdtm1Qxu/\Prkcdtm1Qxu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:76134
|
\Prkcdtm1Qxu/\Prkcdtm1Qxu \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:76134
|
\Prkcitm1Rfar/\Prkci+ \Tg(Ckmm-cre)5Khn/?
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased susceptibility to autoimmune diabetes
|
J:123964
|
\Prkcqtm1Litt/\Prkcqtm1Litt
(B6.129P2-Prkcqtm1Litt)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:129421
|
\Prkdcscid/\Prkdcscid \Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Prkdcscid Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
increased susceptibility to autoimmune diabetes
|
J:81416
|
\Prkdcscid/\Prkdcscid \Tg(INS-Il10)#Sar/0
(NOD.Cg-Prkdcscid Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:66103
|
\Prkdcscid/\Prkdcscid \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
\Psen1tm1Bdes/\Psen1+ \Psen2tm1Bdes/\Psen2tm1Bdes
(involves: 129P2/OlaHsd)
|
autoimmune response
|
J:91235
|
increased anti-single stranded DNA antibody level
|
J:91235
|
increased susceptibility to autoimmune disorder
|
J:91235
|
\Pstpip2Lupo/\Pstpip2Lupo
(either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))
|
increased autoantibody level
|
J:125785
|
\Pstpip2m1Bcs/\Pstpip2m1Bcs
(involves: C57BL/6)
|
autoimmune response
|
J:196534
|
\Ptger4tm1Bhk/\Ptger4tm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:78964
|
rheumatoid arthritis
|
J:78964
|
\Ptgs1tm1Unc/\Ptgs1tm1Unc
(B6.129P2-Ptgs1tm1Unc)
|
decreased susceptibility to induced arthritis
|
J:110716
|
\Ptgs2tm1Unc/\Ptgs2tm1Unc
(B6.129P2-Ptgs2tm1Unc)
|
decreased susceptibility to induced arthritis
|
J:110716
|
\Ptpn6m1Btlr/\Ptpn6m1Btlr
(C57BL/6J-Ptpn6m1Btlr/Mmucd)
|
increased anti-chromatin antibody level
|
J:142845
|
\Ptpn6me-v/\Ptpn6me-v
(C57BL/6J-Ptpn6me-v)
|
rheumatoid arthritis
|
J:20845
|
\Ptpn6me/\Ptpn6me
(C57BL/6J-Ptpn6me/J)
|
autoimmune response
|
J:5579
|
\Ptpn6me/\Ptpn6me
(involves: C3H/HeN * C57BL/6J * NFS)
|
increased autoantibody level
|
J:30994
|
\Ptpn12tm1Vei/\Ptpn12tm1Vei \Tg(Lck-cre)1Cwi/0
(B6.Cg-Ptpn12tm1Vei Tg(Lck-cre)1Cwi)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:163910
|
\Ptpn22tm1.1Draw/\Ptpn22+
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
\Ptpn22tm1.1Draw/\Ptpn22tm1.1Draw
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased anti-insulin autoantibody level
|
J:201448
|
\Ptpn22tm2Achn/\Ptpn22tm2Achn \Ptprctm1Weis/\Ptprctm1Weis
(B6.Cg-Ptprctm1Weis Ptpn22tm2Achn)
|
increased autoantibody level
|
J:147129
|
\Ptprctm1Weis/\Ptprc+
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
\Ptprctm1Weis/\Ptprctm1Weis
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
\Ptprntm1Aln/\Ptprntm1Aln
(NOD.129S4-Ptprntm1Aln)
|
increased susceptibility to autoimmune diabetes
|
J:107161
|
\Ptprz1tm1Schl/\Ptprz1tm1Schl
(involves: 129 * Swiss Webster)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:79860
|
\Rag1tm1Mom/\Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6)
|
autoimmune response
|
J:138466
|
\Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
\Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
\Rag1tm1Mom/\Rag1tm1Mom \Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn \Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
autoimmune response
|
J:134764
|
\Rasgrp1lag/\Rasgrp1lag
(involves: 129 * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:85189
|
\Rasgrp1m1Anu/\Rasgrp1+
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
\Rasgrp1m1Anu/\Rasgrp1m1Anu
(C57BL/6JSfdAnu-Rasgrp1m1Anu)
|
autoimmune response
|
J:104190
|
\Rasgrp1m1Anu/\Rasgrp1m1Anu
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
(B6.Cg-Rasgrp1tm1.1Wz)
|
increased autoantibody level
|
J:225109
|
\Rasgrp4tm1(cre)Rls/\Rasgrp4tm1(cre)Rls
(C57BL/6-Rasgrp4tm1(cre)Rls)
|
decreased susceptibility to induced arthritis
|
J:186519
|
\Rassf5tm1Kina/\Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
increased anti-double stranded DNA antibody level
|
J:168749
|
\Rc3h1san/\Rc3h1san
(either: C57BL/6JSfdAnu-Rc3h1san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))
|
increased anti-double stranded DNA antibody level
|
J:98938
|
increased anti-nuclear antigen antibody level
|
J:98938
|
\Reltm1Hcl/\Reltm1Hcl
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:79107
|
\Rftn1tm1Ayos/\Rftn1tm1Ayos
(B6.Cg-Rftn1tm1Ayos)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
\Rnaseh2bem1Anu/\Rnaseh2b+ \Tlr7em2Anu/\Tlr7+
(C57BL/6NCrl-Rnaseh2bem1Anu Tlr7em2Anu)
|
increased autoantibody level
|
J:324448
|
\Rnf128tm1Cdon/\Rnf128+
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
\Rnf128tm1Cdon/\Rnf128tm1Cdon
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:160681
|
\Rnf128tm1Cdon/\Rnf128tm1Cdon
(involves: 129 * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:160681
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
\Ro60tm1Woln/\Ro60+
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:84627
|
\Ro60tm1Woln/\Ro60tm1Woln
(involves: 129S1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:84627
|
increased anti-double stranded DNA antibody level
|
J:84627
|
increased anti-histone antibody level
|
J:84627
|
increased anti-nuclear antigen antibody level
|
J:84627
|
increased anti-single stranded DNA antibody level
|
J:84627
|
\Rorctm1.1Zsun/\Rorctm1.1Zsun
(B6(129S4)-Rorctm1.1Zsun)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
\Rorctm1Litt/\Rorctm1Litt
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
\Rpl13atm1.1Jesc/\Rpl13atm1.1Jesc
(NOD.129S5(Cg)-Rpl13atm1.1Jesc)
|
decreased susceptibility to autoimmune diabetes
|
J:237822
|
\Rr17tm1.1Cdon/\Rr17tm1.1Cdon
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:181186
|
\Rragcem1Efe/\Rragc+ \Tg(Vav-BCL2)69Jad/0
(Not Specified)
|
decreased susceptibility to autoimmune disorder
|
J:320567
|
\Rubcnem1Dgre/\Rubcnem1Dgre
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Rxratm1Krc/\Rxratm1Krc \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
\S1pr1tm1Jch/\S1pr1tm1Jch \Tg(GFAP-cre)25Mes/?
(involves: C57BL/6J * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
\S1pr1tm1Jch/\S1pr1tm1Jch \Tg(Nes-cre)1Kln/0
(involves: C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
\Satb1tm2Kos/\Satb1tm2Kos \Commd10Tg(Vav1-icre)A2Kio/\Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
increased anti-nuclear antigen antibody level
|
J:252606
|
increased autoantibody level
|
J:252606
|
increased susceptibility to autoimmune disorder
|
J:252606
|
\Scara5tm1Ktry/\Scara5tm1Ktry
(B6N.129X1-Scara5tm1Ktry)
|
increased anti-nuclear antigen antibody level
|
J:195536
|
\Scarf1tm1Tkms/\Scarf1tm1Tkms
(involves: C57BL/6)
|
increased anti-histone antibody level
|
J:208237
|
increased anti-nuclear antigen antibody level
|
J:208237
|
increased anti-single stranded DNA antibody level
|
J:208237
|
increased susceptibility to systemic lupus erythematosus
|
J:208237
|
\Secia1DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia2DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia3FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia4DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia5DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia6DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia7FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Secia8FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
\Selltm1Flv/\Sell+
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:88947
|
\Selltm1Flv/\Selltm1Flv
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune disorder
|
J:88947
|
\Selptm1Bay/\Selptm1Bay
(D1.129S7(B6J)-Selptm1Bay)
|
increased susceptibility to induced arthritis
|
J:57086
|
\Senp1tm1Wami/\Senp1tm1Wami \Tg(Fabp4-cre)#Abel/0
(B6.Cg-Senp1tm1Wami Tg(Fabp4-cre)#Abel)
|
increased anti-insulin autoantibody level
|
J:228009
|
increased susceptibility to autoimmune diabetes
|
J:228009
|
\Shcbp1tm1c(EUCOMM)Wtsi/\Shcbp1tm1c(EUCOMM)Wtsi \Tg(Lck-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
\Shcbp1tm1d(EUCOMM)Wtsi/\Shcbp1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
\Siglecgtm1Lnit/\Siglecgtm1Lnit
(involves: BALB/c)
|
autoimmune response
|
J:123353
|
\Sirt1tm1Mcby/\Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased anti-nuclear antigen antibody level
|
J:160869
|
\Sirt1tm1Mcby/\Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ)
|
increased autoantibody level
|
J:241633
|
\Sit1tm1Lsmn/\Sit1tm1Lsmn
(B6.Cg-Sit1tm1Lsmn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:100408
|
\Skap2Gt(VICTR20)21Lex/\Skap2Gt(VICTR20)21Lex
(B6.129S5-Skap2Gt(VICTR20)21Lex)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:101373
|
\Slamf9em1Isha/\Slamf9em1Isha
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:279164
|
\Slc1a5tm1Tac/\Slc1a5tm1Tac
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:254980
|
\Slc5a2tm1Lex/\Slc5a2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased susceptibility to autoimmune diabetes
|
J:195941
|
\Sle1NZW/\Sle1NZW \Sles1NZW/\Sles1NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:100678
|
\Sle1NZW/\Sle1NZW \Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
\Sle1aC57BL/6J/\Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle1aNZM2410/J/\Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle1bC57BL/6J/\Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle1bNZM2410/J/\Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle1cC57BL/6J/\Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle1cNZB/\Sle1cNZM2410/J
(involves: C57BL/6J * NZB * NZM2410/J)
|
increased autoantibody level
|
J:145133
|
\Sle1cNZM2410/J/\Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
\Sle6NZW/\Sle6NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sle9BXSB/J/\Sle9BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
increased anti-nuclear antigen antibody level
|
J:60445
|
\Sle16129S6/SvEvTac/\Sle16129S6/SvEvTac
(B6.129-Sle16129S6/SvEvTac)
|
increased autoantibody level
|
J:122132
|
increased susceptibility to systemic lupus erythematosus
|
J:122132
|
\Sles1C57BL/6/\Sles1C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles1NZW/\Sles1NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles2C57BL/6/\Sles2C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles2C57BL/6/\Sles2NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles2NZW/\Sles2NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles3C57BL/6/\Sles3C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles3C57BL/6/\Sles3NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles3NZW/\Sles3NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles4C57BL/6/\Sles4C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles4C57BL/6/\Sles4NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Sles4NZW/\Sles4NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
\Slfn8tm1Aki/\Slfn8tm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:258797
|
\Smad7tm1.1Ink/\Smad7tm1.1Ink \Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
\Socs1tm1.1Ayr/\Socs1tm1.1Ayr
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
\Socs1tm1Ayos/\Socs1tm1Ayos \Tg(Lck-cre)1Jtak/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
\Socs3tm1Robb/\Socs3tm1Robb
(involves: C57BL/6)
|
increased susceptibility to induced arthritis
|
J:145513
|
\Sod3tm1Mrkl/\Sod3tm1Mrkl
(D1.129P2-Sod3tm1Mrkl)
|
increased susceptibility to induced arthritis
|
J:106273
|
\Spink14tm1e(KOMP)Wtsi/\Spink14tm1e(KOMP)Wtsi
(C57BL/6N-Spink14tm1e(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Spntm1Bam/\Spntm1Bam
(B6;129S4-Spntm1Bam/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:86932
|
\Spp1tm1Blh/\Spp1tm1Blh
(B6.129S6-Spp1tm1Blh)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116272
|
\St14tm2Bug/\St14tm3Bug \Tg(MMTV-cre)4Mam/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)
|
increased anti-nuclear antigen antibody level
|
J:213072
|
increased autoantibody level
|
J:213072
|
\Stat4tm1Gru/\Stat4tm1Gru
(NOD.129S2-Stat4tm1Gru)
|
decreased susceptibility to autoimmune diabetes
|
J:90600
|
\Stat4tm1Gru/\Stat4tm1Gru \Tg(Ins2-GP)34-20Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
abnormal susceptibility to autoimmune disorder
|
J:107047
|
\Stat4tm1Gru/\Stat4tm1Gru \Tg(Ins2-NP)25-3Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:107047
|
\Stat4tm1Jni/\Stat4tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
\Stat4tm1Jni/\Stat4tm1Jni \Stat6tm1Jni/\Stat6tm1Jni
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:96338
|
\Stat6tm1Jni/\Stat6tm1Jni
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
\Stim1tm1Kuro/\Stim1tm1Kuro \Stim2tm1.1Kuro/\Stim2tm1.1Kuro \Cd79atm1(cre)Reth/\Cd79a+
(involves: BALB/c * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172608
|
\Stk17btm1Hed/\Stk17btm1Hed
(B6.129X1-Stk17btm1Hed)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
\Swap70tm1Jess/\Swap70tm1Jess
(involves: 129T2/SvEms * 129X1/SvJ)
|
increased autoantibody level
|
J:71160
|
\Swrl2SWR/\Swrl2SWR
(involves: NZB * SWR)
|
increased anti-single stranded DNA antibody level
|
J:96060
|
\Swrl3NZB/\Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
\Swrl3SWR/\Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
\Syktm2.1(ZAP70)Fkfr/\Syktm2.1(ZAP70)Fkfr
(B6.129-Syktm2.1(ZAP70)Fkfr)
|
increased anti-insulin autoantibody level
|
J:188422
|
\Syt7tm1Nan/\Syt7tm1Nan
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:85201
|
increased susceptibility to autoimmune disorder
|
J:85201
|
\Syvn1tm1Tn/\Syvn1+
(D1.Cg-Syvn1tm1Tn)
|
decreased susceptibility to induced arthritis
|
J:86009
|
\Tanktm1Aki/\Tanktm1Aki
(involves: 129/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:151757
|
increased anti-nuclear antigen antibody level
|
J:151757
|
\Tap1tm1Arp/\Tap1tm1Arp X/\Yaa
(BXSB.129S2(B6)-Tap1tm1Arp/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
\Tarm1tm1Yiw/\Tarm1tm1Yiw
(involves: C57BL/6 * C57BL/6NSlc)
|
decreased susceptibility to induced arthritis
|
J:301164
|
\Taslem1Bcgen/\Taslem1Bcgen
(BALB/cJ-Taslem1Bcgen)
|
decreased susceptibility to systemic lupus erythematosus
|
J:363059
|
\Tbc1d10ctm1.1Psou/\Tbc1d10ctm1.2Psou \Cd79atm1(cre)Reth/\Cd79a+
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
\Tbc1d10ctm1.2Psou/\Tbc1d10ctm1.2Psou
(involves: 129S2/SvPas * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
\Tbk1tm1Arte/\Tbk1tm1Arte \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:188560
|
increased anti-nuclear antigen antibody level
|
J:188560
|
\Tbx21tm1Glm/\Tbx21tm1Glm
(C.129S6-Tbx21tm1Glm/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:111932
|
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(B6.129-Tcra-Jtm1Tgi)
|
decreased susceptibility to induced arthritis
|
J:99107
|
\Tcratm1Mjo/\Tcra+
(NOD.129P2-Tcratm1Mjo)
|
decreased susceptibility to autoimmune diabetes
|
J:108590
|
\Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:111129
|
increased anti-nuclear antigen antibody level
|
J:111129
|
increased autoantibody level
|
J:111129
|
\Tcrbtm1Mom/\Tcrbtm1Mom \Tcrdtm1Mom/\Tcrdtm1Mom
(B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J)
|
decreased autoantibody level
|
J:187766
|
\Tcrbtm1Mom/\Tcrbtm1Mom \Tcrdtm1Mom/\Tcrdtm1Mom \Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(B6.129P2-Tcrbtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg Tcrdtm1Mom)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
\Tcrbtm1Mom/\Tcrbtm1Mom \Tcrdtm1Mom/\Tcrdtm1Mom \Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(B6.129-Tcrbtm1Mom Traf3ip2tm1.1Lix Tcrdtm1Mom)
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
\Tet1tm1.2Jae/\Tet1tm1.2Jae \Tet2tm1.1Iaai/\Tet2tm1.1Iaai \Tet3tm1.1Yzhg/\Tet3tm1.1Yzhg \Tg(Rorc-cre)1Litt/0
(involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)
|
increased susceptibility to autoimmune disorder
|
J:333574
|
\Tg(ACTB-TNFRSF6B)754Jwu/?
(B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)
|
increased anti-double stranded DNA antibody level
|
J:148162
|
increased autoantibody level
|
J:148162
|
\Tg(BCL2)22Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased susceptibility to autoimmune disorder
|
J:93111
|
\Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased susceptibility to autoimmune disorder
|
J:93111
|
\Tg(CAG-C1qtnf6)#Yiw/0
(involves: C57BL/6JJcl)
|
decreased susceptibility to induced arthritis
|
J:227217
|
\Tg(CAG-p35)1Miur/0
(involves: C57BL/6)
|
autoimmune response
|
J:126593
|
\Tg(CAG-p35)1Miur/0 \Tg(Mbp-cre)29Miur/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126593
|
\Tg(CAG-SYVN1)1Tn/?
(D1.Cg-Tg(CAG-SYVN1)1Tn)
|
rheumatoid arthritis
|
J:86009
|
\Tg(CD2-Lrch1)#Liux/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
\Tg(CD2-Rorc)#Staka/0
(involves: C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:230700
|
increased autoantibody level
|
J:230700
|
increased susceptibility to autoimmune disorder
|
J:230700
|
\Tg(Cd2-Smad7)#Chbe/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:217939
|
increased autoantibody level
|
J:217939
|
increased susceptibility to autoimmune disorder
|
J:217939
|
\Tg(Cd4-CD4)2362Litt/0 \Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2 * SJL)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
\Tg(Cd4-DsRed)4Lt/0
(NOD/ShiLt-Tg(Cd4-DsRed)4Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:127785
|
\Tg(CD4-Il17re)#Cdon/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
\Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)
|
increased anti-nuclear antigen antibody level
|
J:97554
|
\Tg(Cd152Ig)1Jbs/0
(involves: C3H * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
\Tg(CKMM-tTA)A3Rhvh/0 \Tg(tetO-H2-K1)#Papl/0
(B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)
|
increased anti-nuclear antigen antibody level
|
J:205907
|
increased autoantibody level
|
J:205907
|
\Tg(Col2a1-Mir140)#Asah/0
(C57BL/6-Tg(Col2a1-Mir140)#Asah)
|
decreased susceptibility to induced arthritis
|
J:160358
|
\Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
|
increased autoantibody level
|
J:117018
|
increased susceptibility to autoimmune disorder
|
J:117018,
J:145185
|
\Tg(FCGR2A)11Mkz/\Tg(FCGR2A)11Mkz
(involves: C57BL/6 * SJL)
|
increased anti-histone antibody level
|
J:136516
|
increased susceptibility to induced arthritis
|
J:136516
|
\Tg(H2-Ea-G6pc2)69Tkay/?
(NOD-Tg(H2-Ea-G6pc2)69Tkay)
|
increased anti-insulin autoantibody level
|
J:117352
|
increased susceptibility to autoimmune diabetes
|
J:117352
|
\Tg(H2-Ea-Ins2)1Wehi/\Tg(H2-Ea-Ins2)1Wehi
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
|
decreased anti-insulin autoantibody level
|
J:117352
|
\Tg(H2-Ead)5Lt/0
(NOD/ShiLt-Tg(H2-Ead)5Lt)
|
autoimmune response
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
\Tg(H2-Ead)12Lt/0
(NOD/ShiLt-Tg(H2-Ead)12Lt)
|
autoimmune response
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
\Tg(H2-K-MC159/EGFP)13Fkmc/\Tg(H2-K-MC159/EGFP)13Fkmc
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:138050
|
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
\Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
\Tg(HLA-B27)30-4Trg/?
(involves: C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:59245
|
\Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz/\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz
(involves: C57BL/6 * C57BL/10Sn * SJL/J)
|
increased autoantibody level
|
J:108635
|
increased susceptibility to induced arthritis
|
J:108635
|
\Tg(Igh3H9)41Mwg/?
(involves: C57BL/6 * SJL)
|
increased anti-single stranded DNA antibody level
|
J:119625
|
\Tg(Igh-6-Cd80)1Gjf/0
(NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:131077
|
\Tg(Igh-6/Igh-V125)2Jwt/0 \Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
\Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)
|
decreased susceptibility to autoimmune diabetes
|
J:91865
|
\Tg(Igh-V-CD40lg)#Tsub/0
(C57BL/6-Tg(Igh-V-CD40lg)#Tsub)
|
increased anti-double stranded DNA antibody level
|
J:128824
|
increased anti-histone antibody level
|
J:128824
|
increased anti-single stranded DNA antibody level
|
J:128824
|
\Tg(Igh-V-CD40lg)#Tsub/0
(involves: C57BL/6)
|
increased autoantibody level
|
J:89855
|
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg
(NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)
|
increased susceptibility to autoimmune diabetes
|
J:80859
|
\Tg(IghH280)48Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
\Tg(IghH280)48Dvs/? \Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
\Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
\Tg(Ins1-Cat,Tyr)25Pne/0
(NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)
|
increased susceptibility to autoimmune diabetes
|
J:108415
|
\Tg(Ins1-EGFP/GH1)14Hara/0
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
\Tg(Ins1-EGFP/GH1)14Hara/\Tg(Ins1-EGFP/GH1)14Hara
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
\Tg(Ins2*Y16A)1Ell/0
(NOD-Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
\Tg(Ins2*Y16A)3Ell/0
(NOD-Tg(Ins2*Y16A)3Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
\Tg(Ins2-CD80)3B7Flv/?
(involves: C57BL/6 * CBA/Ca * NOD/Caj)
|
increased susceptibility to autoimmune diabetes
|
J:26618
|
\Tg(Ins2-CD80)3B7Flv/0 \Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-CD80)3B7Flv/0 \Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-CD86)12B70Flv/0
(involves: C57BL/6 * CBA/Ca)
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-CD86)12B70Flv/0 \Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-CD86)12B70Flv/0 \Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-Cd274)2Mdos/?
(NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)
|
increased susceptibility to autoimmune diabetes
|
J:118934
|
\Tg(Ins2-cre)5Lt/0
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
\Tg(Ins2-cre)5Lt/\Tg(Ins2-cre)5Lt
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
\Tg(Ins2-crmA)27Ngkh/?
(NOD-Tg(Ins2-CrmA)27Ngkh)
|
increased susceptibility to autoimmune diabetes
|
J:132052
|
\Tg(Ins2-E3)1Dvs/?
(NOD.Cg-Tg(Ins2-E3)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:68996
|
\Tg(Ins2-E3*309)5Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*309)5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
\Tg(Ins2-E3*704)2Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*704)2Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
\Tg(Ins2-E3*734)3Dvs/0
(NOD/ShiLtDvs-Tg(Ins2-E3*734)3Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
\Tg(Ins2-E3*734)4Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*734)4Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
\Tg(Ins2-Fas*I246N)1Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
\Tg(Ins2-Fas*I246N)1Ach/0 \Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
\Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fasl)24Ach/J)
|
increased susceptibility to autoimmune diabetes
|
J:78679,
J:81416
|
\Tg(Ins2-GAD2)2Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)2Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:100251
|
\Tg(Ins2-GP)34-20Olds/0
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
\Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
\Tg(Ins2-Iapp)6Soel/\Tg(Ins2-Iapp)6Soel
(involves: FVB/N)
|
decreased susceptibility to autoimmune diabetes
|
J:130022
|
\Tg(Ins2-IAPP)RHFSoel/\Tg(Ins2-IAPP)RHFSoel
(involves: FVB/N)
|
increased susceptibility to autoimmune diabetes
|
J:130022
|
\Tg(Ins2-NP)25-3Olds/0
(involves: BALB/c * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:81287
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
\Tg(Ins2-OVA)59Wehi/?
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
\Tg(Ins2-OVA)307Wehi/?
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
\Tg(Ins2-OVA)307Wehi/0 \Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * C57BL/6JWehi)
|
autoimmune response
|
J:99451
|
\Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
\Tg(INS-Il10)#Sar/0 \Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
\Tg(INS-Il10)#Sar/0 \Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO/CMV-Tslp)#Sfz/0
(C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)
|
increased autoantibody level
|
J:182756
|
increased susceptibility to autoimmune hemolytic anemia
|
J:182756
|
\Tg(Lck-Socs3)1Kubo/0
(Not Specified)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
\Tg(Lck-Stk17b)26.1Wals/?
(B6.Cg-Tg(Lck-Stk17b)26.1Wals)
|
increased anti-nuclear antigen antibody level
|
J:149973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149973
|
\Tg(Lck-Tnfsf14)24Yxf/?
(C57BL/6-Tg(Lck-Tnfsf14)24Yxf)
|
increased anti-double stranded DNA antibody level
|
J:129951
|
increased anti-nuclear antigen antibody level
|
J:128976
|
increased autoantibody level
|
J:129951
|
\Tg(Lck-Tslp)1Chea/0
(B6.Cg-Tg(Lck-Tslp)1Chea)
|
increased anti-nuclear antigen antibody level
|
J:72982
|
\Tg(Lck/Emu-Rftn1)1Ayos/?
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
\Tg(Mir125a)#Smoc/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
\Tg(Plp1-Eif2ak3*)18Pop/0
(C57BL/6J-Tg(Plp1-Eif2ak3*)18Pop)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238042
|
\Tg(Psp-Rbbp4)1Yoha/0
(involves: C57BL/6)
|
increased autoantibody level
|
J:141378
|
increased susceptibility to autoimmune disorder
|
J:141378
|
\Tg(SV40-Igh-64C8)H3Hon/0 \Tg(SV40-Igk4C8)L1Hon/0
(involves: C57BL/6)
|
increased anti-erythrocyte antigen antibody level
|
J:139864
|
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:83278
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83278
|
\Tg(Tcra,Tcrb)24Efro/0
(D1.Cg-Tg(Tcra,Tcrb)24Efro)
|
autoimmune response
|
J:104243
|
increased autoantibody level
|
J:104243
|
increased susceptibility to autoimmune disorder
|
J:104243
|
\Tg(TcraAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
\Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
\Tg(TcraAV19AJ33)1Shima/?
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
\Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
rheumatoid arthritis
|
J:36815
|
\Tg(TcraTcrbNY4.1)1Pesa/0
(NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)
|
increased susceptibility to autoimmune diabetes
|
J:108768
|
\Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
\Tg(TcrbBL17)1Lmor/\Tg(TcrbBL17)1Lmor
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz
(NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)
|
autoimmune response
|
J:71050
|
\Tg(tetO-MAP2K1)#Ahsa/? \Tg(CD2-rtTA)CRza/?
(involves: C57BL/6 * C57BL/10 * CBA * SJL)
|
increased anti-double stranded DNA antibody level
|
J:174339
|
\Tg(Tlr7)1Boll/0
(involves: C57BL/6)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
X/\Tg(Tlr7)6Boll
(involves: C57BL/6)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
\Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J)
|
increased anti-double stranded DNA antibody level
|
J:58798
|
increased anti-single stranded DNA antibody level
|
J:58798
|
increased autoantibody level
|
J:58798
|
\Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased autoantibody level
|
J:114782
|
\Tg(Tnfsf13b)1Fma/?
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
\Tgfb1tm3.1Flv/\Tgfb1tm3.1Flv \Tg(Cd4-cre)1Cwi/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm \Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
autoimmune response
|
J:148747
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm \Tnfrsf4tm2(cre)Nik/\Tnfrsf4+ \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
\TgTn(pb-CAG-Gm614)#Cya/0
(involves: C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:307345
|
\Thbs1tm1Hyn/\Thbs1tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:153126
|
\Thop1Gt(CSG163)Byg/\Thop1Gt(CSG163)Byg
(B6.129P2-Thop1Gt(CSG163)Byg)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:290567
|
\Tigittm1Sdl/\Tigittm1Sdl
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
\Tigittm1Sdl/\Tigittm1Sdl \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
\Timd4tm1Kuch/\Timd4tm1Kuch
(C57BL/6-Timd4tm1Kuch)
|
increased anti-double stranded DNA antibody level
|
J:160747
|
\Timd4tm1Kuch/\Timd4tm1Kuch
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
\Tlr4Lps-d/\Tlr4Lps-d
(involves: C3H/HeJ)
|
increased susceptibility to induced arthritis
|
J:96356
|
\Tlr4tm1Aki/\Tlr4tm1Aki
(C.129P2-Tlr4tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
\Tlr5tm1Flv/\Tlr5tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:158055
|
\Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
\Tlr7em2Anu/\Tlr7+
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
\Tlr7em2Anu/\Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
\Tlr7tm1Flv/\Tlr7tm1Flv
(B6.129S1-Tlr7tm1Flv)
|
decreased anti-insulin autoantibody level
|
J:165267
|
\Tlr8/Tlr7tm1Vlcg/\Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
\Tlr8/Tlr7tm1Vlcg/\Tlr7+ \Tlr8/Tlr7tm1Vlcg/\Tlr8tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
\Tlr8/Tlr7tm1Vlcg/\Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
\Tlr8tm1Vlcg/\Tlr8tm1Vlcg
(B6.129S1-Tlr8tm1Vlcg)
|
increased anti-double stranded DNA antibody level
|
J:165267
|
increased anti-nuclear antigen antibody level
|
J:165267
|
\Tlr9tm1Aki/\Tlr9tm1Aki
(B6.129P2-Tlr9tm1Aki)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
\Tmem178tm1Lex/\Tmem178tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:228311
|
\TnfBpsm1/\Tnf+
(involves: C57BL/6)
|
rheumatoid arthritis
|
J:226052
|
\TnfBpsm1/\TnfBpsm1
(involves: C57BL/6)
|
rheumatoid arthritis
|
J:226052
|
\Tnftm1.1Sned/\Tnftm1.1Sned \Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
\Tnftm1.1Sned/\Tnftm1.1Sned \Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
\Tnftm1Gkl/\Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
\Tnftm1Gkl/\Tnftm1Gkl
(involves: 129S/SvEv)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
\Tnftm1Gkl/\Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
\Tnftm1Jods/\Tnftm1Jods
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:44545,
J:98591
|
\Tnftm1Jods/\Tnftm1Jods
(C57BL/6-Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
\Tnftm1Jods/\Tnftm1Jods
(C57BL/6-Ltatm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
\Tnftm1Ljo/\Tnftm1Ljo
(involves: 129S1/Sv)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
\Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
\Tnftm2Gkl/\Tnf+ \Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
\Tnftm2Gkl/\Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
\Tnftm2Jods/\Tnftm2Jods
(C57BL/6-Tnftm2Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98591
|
\Tnftm3Gkl/\Tnftm3Gkl
(involves: 129S/SvEv * C57BL/6)
|
autoimmune response
|
J:114740
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
\Tnfaip3tm2Ama/\Tnfaip3tm2Ama \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased autoantibody level
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92470
|
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt \Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx \Tnfrsf1btm1Imx/\Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
decreased susceptibility to induced arthritis
|
J:120707
|
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak \Tnip1Gt(E059E05)Wrst/\Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
\Tnfrsf13btm1Vmd/\Tnfrsf13btm1Vmd
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:82331
|
increased anti-nuclear antigen antibody level
|
J:82331
|
\Tnfsf4tm1Shr/\Tnfsf4tm1Shr
(NOD.129S4-Tnfsf4tm1Shr)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
\Tnfsf10tm1Mjs/\Tnfsf10tm1Mjs
(B6.129-Tnfsf10tm1Mjs)
|
increased susceptibility to autoimmune diabetes
|
J:82145
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:101672
|
increased susceptibility to induced arthritis
|
J:82145
|
\Tnfsf13tm1Pod/\Tnfsf13tm1Pod
(B6.Cg-Tnfsf13tm1Pod)
|
decreased susceptibility to induced arthritis
|
J:141374
|
\Tnfsf15tm1Cdon/\Tnfsf15tm1Cdon
(B6.129-Tnfsf15tm1Cdon)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136280
|
\Tnfsf15tm1Hluo/\Tnfsf15tm1Hluo
(D1LacJ.129(B6)-Tnfsf15tm1Hluo)
|
decreased susceptibility to induced arthritis
|
J:207029
|
\Tnip1Gt(E059E05)Wrst/\Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:180054
|
increased anti-nuclear antigen antibody level
|
J:180054
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
\Tnip1m1Btlr/\Tnip1m1Btlr
(C57BL/6J-Tnip1m1Btlr)
|
increased anti-double stranded DNA antibody level
|
J:265175
|
\Tnip1tm1.1Pcoh/\Tnip1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:176826
|
\Tnip1tm1.1Pcoh/\Tnip1tm1.1Pcoh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:176826
|
increased anti-nuclear antigen antibody level
|
J:176826
|
\Tpp2tm1.1Gnie/\Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac)
|
increased anti-nuclear antigen antibody level
|
J:221205
|
increased autoantibody level
|
J:221205
|
\Tpsab1m1/\Tpsab1m1 \Tpsb2tm1(cre)Adch/\Tpsb2tm1(cre)Adch
(B6.Cg-Tpsb2tm1(cre)Adch Tpsab1m1)
|
decreased susceptibility to induced arthritis
|
J:142880
|
\Tpsb2tm1.1Mfg/\Tpsb2tm1.1Mfg
(B6.129-Tpsb2tm1.1Mfg)
|
decreased susceptibility to induced arthritis
|
J:142880
|
\Traf3tm1Bshp/\Traf3tm1Bshp \Cd19tm1(cre)Cgn/\Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
|
autoimmune response
|
J:124329
|
increased anti-double stranded DNA antibody level
|
J:124329
|
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(involves: 129/Sv * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:93923
|
increased anti-histone antibody level
|
J:93923
|
increased anti-single stranded DNA antibody level
|
J:93923
|
increased autoantibody level
|
J:93923
|
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(C.129-Traf3ip2tm1.1Lix)
|
increased autoantibody level
|
J:138560
|
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(B6.129-Traf3ip2tm1.1Lix)
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased anti-nuclear antigen antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix \Tnfsf13btm1Msc/\Tnfsf13btm1Msc
(involves: 129 * 129S2/SvPas * BALB/c)
|
increased autoantibody level
|
J:138560
|
\Traf3ip2tm1Sbn/\Traf3ip2tm1Sbn
(either: B6.129-Traf3ip2tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))
|
decreased susceptibility to autoimmune disorder
|
J:144320
|
\Trem1tm1(KOMP)Vlcg/\Trem1tm1(KOMP)Vlcg
(C57BL/6N-Trem1tm1(KOMP)Vlcg/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
\Trex1em3Gpt/\Trex1em3Gpt
(C57BL/6JGpt-Trex1em3Gpt)
|
increased susceptibility to autoimmune disorder
|
J:330879
|
\Trex1tm1.1Fwpe/\Trex1tm1.1Fwpe
(involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:220965
|
increased susceptibility to systemic lupus erythematosus
|
J:220965
|
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd)
|
increased autoantibody level
|
J:202757
|
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:181257
|
increased susceptibility to systemic lupus erythematosus
|
J:181257
|
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to autoimmune disorder
|
J:243357
|
\Trim21tm1Mwah/\Trim21tm1Mwah
(C57BL/6-Trim21tm1Mwah)
|
autoimmune response
|
J:151775
|
increased autoantibody level
|
J:151775
|
\Trim25tm1Mura/\Trim25+ \Usp15L749R/\Usp15+
(involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
\Tsc22d3tm1.2Efmd/Y
(Not Specified)
|
abnormal susceptibility to autoimmune disorder
|
J:201728
|
\Tusc2tm1Avi/\Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
\Tusc2tm1Avi/\Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
\Tusc2tm1Avi/\Tusc2tm1Avi
(involves: 129S1/Sv)
|
increased susceptibility to autoimmune disorder
|
J:309768
|
\Tyk2E775K/\Tyk2E775K
(B10.D1-H2q/SgJ)
|
decreased susceptibility to induced arthritis
|
J:69051
|
\Tyrobptm1Lll/\Tyrobptm1Lll
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:64763
|
\Tyrobptm1Lll/\Tyrobptm1Lll
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:158811
|
\Tyrobptm1Ttk/\Tyrobptm1Ttk
(B6.129P2-Tyrobptm1Ttk)
|
increased anti-double stranded DNA antibody level
|
J:177613
|
increased autoantibody level
|
J:177613
|
\Ubash3btm1Jni/\Ubash3btm1Jni \Ubash3atm1Jni/\Ubash3atm1Jni
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
\Unc93b1tm1.1Kmiy/\Unc93b1tm1.1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:174308
|
increased autoantibody level
|
J:174308
|
\Usp15L749R/\Usp15+
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
\Usp15L749R/\Usp15L749R
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
\Usp15L749R/\Usp15tm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
\Usp15tm1Pgrs/\Usp15tm1Pgrs
(Not Specified)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
\Usp25Gt(RRS805)Byg/\Usp25Gt(RRS805)Byg
(involves: 129P2/OlaHsd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:188557
|
\Vdrtm1Ska/\Vdrtm1Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
decreased susceptibility to autoimmune diabetes
|
J:112519
|
\Vdrtm1Ska/\Vdrtm1Ska
(NOD.Cg-Vdrtm1Ska/CmatJ)
|
increased susceptibility to autoimmune diabetes
|
J:127787
|
\Vsig4tm1Gne/\Vsig4tm1Gne
(C57BL/6-Vsig4tm1Gne)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
\Vsirtm1Lex/\Vsirtm1Lex \Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
\Vtcn1tm1Xxz/\Vtcn1tm1Xxz
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:177612
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177612
|
\Vwftm1Wgr/\Vwftm1Wgr
(B6.129S2-Vwftm1Wgr)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:140334
|
\Wastm1Itl/Y
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wastm1Itl/\Wastm1Itl
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wastm1Sbs/Y
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wastm1Sbs/Y
(involves: 129S6/SvEvTac * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
\Wastm1Sbs/\Wastm1Sbs
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wastm1Sbs/\Wastm1Sbs
(involves: 129S6/SvEvTac * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
\Wastm2Itl/Y
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wastm2Itl/\Wastm2Itl
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
\Wipf1tm1Geha/\Wipf1tm1Geha
(involves: 129S6/SvEvTac * C57BL/6)
|
increased autoantibody level
|
J:116168
|
\Xcl1tm1.1Dnax/\Xcl1tm1.1Dnax
(either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))
|
autoimmune response
|
J:176844
|
\Xkrxtm1b(EUCOMM)Wtsi/\Xkrxtm1b(EUCOMM)Wtsi
(C57BL/6N-Xkrxtm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
X/\Yaa
((NZB x BXSB)F1)
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:6235
|
increased autoantibody level
|
J:6235
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/\Yaa
((SJL/J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/\Yaa
((C57BL/6J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/\Yaa
(involves: BXSB * NZB)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/\Yaa
(BXSB/MpJ)
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to autoimmune disorder
|
J:108760,
J:6235
|
X/\Yaa
((NZW x SB)F1)
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/\Yaa
((NZW x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/\Yaa
(BXSB/MpJScr)
|
increased anti-nuclear antigen antibody level
|
J:10973
|
increased susceptibility to autoimmune disorder
|
J:10973
|
\YaailNZW/Ola/?
(involves: C57BL/6Ola * NZW/Ola)
|
increased anti-double stranded DNA antibody level
|
J:52110
|
\Zap70m1Saka/\Zap70m1Saka
(involves: BALB/c)
|
increased autoantibody level
|
J:86607
|
increased susceptibility to induced arthritis
|
J:154166
|
rheumatoid arthritis
|
J:86607
|
\Zap70m1Saka/\Zap70tm2.1Weis
(involves: 129S4/SvJae * BALB/c)
|
decreased susceptibility to induced arthritis
|
J:154166
|
\Zc3h12atm1Aki/\Zc3h12atm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:147868
|
increased anti-nuclear antigen antibody level
|
J:147868
|
\Zc3h12atm1c(EUCOMM)Hmgu/\Zc3h12atm1c(EUCOMM)Hmgu \Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
(involves: C57BL/6 * C57BL/6N * DBA)
|
increased anti-nuclear antigen antibody level
|
J:304105
|
increased autoantibody level
|
J:304105
|
\Zc3h12dtm1Tom/\Zc3h12dtm1Tom
(B6.Cg-Zc3h12dtm1Tom)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209383
|
\Zfp36tm2.1Pjb/\Zfp36tm2.1Pjb
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:229078
|
decreased susceptibility to induced arthritis
|
J:229078
|
\Zranb1tm1c(EUCOMM)Hmgu/\Zranb1tm1c(EUCOMM)Hmgu \Tg(Itgax-cre)1-1Reiz/0
(involves: 129S4/SvJaeSor * C57BL/6N * CBA)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|
\Zranb1tm1d(EUCOMM)Hmgu/\Zranb1tm1d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|